Retrodialysis of Pharmacological Agents Mitigates Tissue Damage during Brain Microdialysis and Preserves Dopamine Activity in Surrounding Tissue by Nesbitt, Kathryn M
 Retrodialysis of Pharmacological Agents Mitigates Tissue Damage during Brain 
Microdialysis and Preserves Dopamine Activity in Surrounding Tissue 
 
 
 
 
 
 
 
 
by 
Kathryn M. Nesbitt 
B.S. Chemistry, St. John Fisher College, 2010 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of the 
Kenneth P. Dietrich School of Arts and Sciences in partial fulfillment  
Of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2015 
 
 ii 
UNIVERSITY OF PITTSBURGH 
DIETRICH SCHOOL OF ARTS AND SCIENCES 
 
 
 
 
 
 
 
 
This dissertation was presented 
 
by 
 
 
Kathryn M. Nesbitt 
 
 
 
It was defended on 
April 14, 2015 
and approved by 
Shigeru Amemiya, Professor, Department of Chemistry 
Renã Robinson, Professor, Department of Chemistry 
Xinyan Tracy Cui, Professor, Department of Bioengineering 
Dissertation Advisor: Adrian C. Michael, Professor, Department of Chemistry 
 
 
 iii 
Copyright © by Kathryn M. Nesbitt 
2015 
 iv 
 
Microdialysis is a powerful technique used to recover analytes from the brain.  
Microdialysis is compatible with multiple detectors allowing simultaneous analysis of 
neurotransmitters, metabolites, neuropeptides, and amino acids.  The use of microdialysis has 
made advances in understanding brain function and diseases and is currently used to monitor 
traumatic brain injured patients. However, microdialysis probe implantation causes a penetration 
injury eliciting a foreign body response in the surrounding brain tissue.  Tissue around the probe 
becomes unhealthy which brings into question, how the state of the tissue around the probe 
effects analytes that are recovered by microdialysis. 
Dopamine, a neurotransmitter involved in a variety of physiological functionality and 
neurological disorders, is often recovered using microdialysis.  Dopamine is electroactive, and 
can also be measured using carbon fiber microelectrodes coupled with voltammetry. The small 
size of these electrodes allows for high spatial resolution without damaging the tissue.  Using 
microelectrodes our lab has previously found that probe implantation creates a gradient of 
reductions in evoked dopamine responses the closer the electrode is to the probe.  This 
dissertation builds off of this finding, with the goal of mitigating the penetration injury to 
preserve dopamine neurotransmission.  First, it was discovered that probe implantation 
completely abolished evoked dopamine responses near probes. Administration of a dopamine 
transporter inhibitor showed that terminals survive probe implantation justifying our efforts to 
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mitigate probe induced tissue damage. Retrodialysis of an anti-inflammatory drug 
dexamethasone and a reactive oxygen species scavenger XJB-5-131 prevented dopamine 
terminal loss and preserved evoked dopamine responses for four hours. Further work proved that 
dexamethasone preserves evoked dopamine release for up to 24 hours. As dexamethasone is a 
steroid that could potentially affect neurotransmission, other pharmacological agents were 
investigated, all proving to improve evoked DA responses in tissue surrounding probes.  
Pharmacological mitigation of tissue damage provides new insight into acute extenuation of 
probe induced damage which has the potential to successfully mitigate chronic implantation for 
long-term in vivo monitoring of neurochemicals. 
In a separate study, microelectrodes were used to spatially map dopamine responses in 
the rat brain. Distinct dopamine kinetics exist in sub-regions of the striatum that correlate to 
patch-matrix compartments. 
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1.0  INTRODUCTION 
1.1.1 Microdialysis 
Microdialysis is a widely used technique in the field of neurochemistry. In general, microdialysis 
is used to recover analytes in the extracellular space of the brain. A solution similar to that of the 
area being sampled is perfused through a semi-permeable membrane. As the fluid diffuses out of 
the membrane small molecules diffuse into the membrane and are collected through outlet 
tubing. Microdialysis can be coupled with detection methods such as high-performance liquid 
chromatography, capillary electrophoresis, and mass spectrometry for analysis. This technique 
allows for simultaneous detection of multiple small molecules. One drawback is that 
microdialysis is slower than most dynamic central nervous system processes however, 
microdialysis sampling and analysis is becoming faster, with reported sample times of less than a 
minute.1 Consequently it has been applied in numerous studies involving the brain. 
Microdialysis explores brain function often times by recovery of neurotransmitters such 
as dopamine.2-4 Experiments involving the collection of neurotransmitters have allowed for the 
study of drug addiction and systemic effects of drugs of the neurochemistry of the brain.5 
Retrodialysis or the use of the probe to delivery agents to the brain allows for local delivery and 
analysis of drugs to a particular brain region simultaneously.6 Neurological diseases, such as 
Parkinson’s disease, have also been studied using microdialysis.7 Recently, microdialysis has 
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been used to examine traumatic brain injuries (TBI) in human patients. The diversity of 
microdialysis membranes allows for the recovery and analysis of a variety of analytes pertinent 
to understanding TBI, including amino acids, glucose and lactate and extracellular metabolites.8-
10 
1.1.2 Device Implantation 
Unfortunately, implantation of any type of neuronal device for analysis causes a cellular 
response that can be damaging to the ultrastructure of the brain directly surrounding the implant. 
Astrocytes and microglia make up the majority of the cellular response to the foreign body. An 
initial reaction to implantation is observed followed by an unrelenting response weeks after 
implantation.11 Devices have a limited functional lifetime in the brain defined by the glial barrier 
that encapsulates the device and prevents it from accessing the brain. Alterations in device 
material, shape and size have led to improvements to the cellular response and longevity of the 
device,12-13 however development of a more permanent solution is still of importance. 
This disadvantage is specifically a concern for microdialysis because of the larger size of 
microdialysis probes. Probes cause penetration injuries when implanted into the brain.14-15 
Analysis of tissue surrounding microdialysis probes implanted in the striatum by light 
microscopy unveiled tissue damage 1.4 mm and neuronal loss 400 µm from the probe track.16 
Not only does the large size of the microdialysis probe cause damage, but the tissue response to a 
foreign object also contributes to the severity of the injury. Probe implantation restricts blood 
flow (ischemia) and triggers gliosis.17-18 Therefore, the tissue sampled by microdialysis is not in 
its normal state. Even though the injury associated with microdialysis probe implantation is 
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significant, it is important to note that overall brain function and animal behavior does not 
change, making it safe for clinical use.19 
Efforts to reduce the tissue response associated with neural device implantation have 
been made. Anti-inflammatories for example reduce nitric oxide production from microglia.20 
Dexamethasone, an anti-inflammatory and immunosuppessant glucocorticoid, decreased gliosis 
and ischemia caused by neuronal device implantation. Both systemic treatment with 
dexamethasone and device coating with dexamethasone have been effective.21-23 Dexamethasone 
was neuroprotective for dopamine terminals in the striatum during inflammatory reactions in 
rodent models for Parkinson’s disease.7, 24 Retrodialysis of dexamethasone extended 
microdialysis probe function by two days in a subcutaneous study.25 In terms of probe 
implantation in the brain, dexamethasone by retrodialysis significantly inhibited gliosis and 
ischemia.26 
1.1.3 Dopamine 
Dopamine is a well-studied neurotransmitter in the brain that is often recovered from the brain 
by microdialysis. In the striatum, dopamine is synthesized and packaged into vesicles in 
dopamine terminals. Dopamine is released in the striatum upon arrival of an action potential. 
During an action potential, vesicles containing dopamine fuse to presynaptic membranes and 
release their contents into the synapse. The extracellular concentration of dopamine is regulated 
by dopamine receptors and transporters. Dopamine autoreceptors (D2 receptors) inhibit 
dopamine release once a sufficient concentration is reached. Dopamine transporters (DAT) are 
responsible for the reuptake of dopamine from the extracellular space back into the cell. During 
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stimulation to induce an action potential, evoked release, autoinhibition and uptake regulate the 
extracellular concentration of dopamine.27 
1.1.4 Dopamine Detection 
Fast scan cyclic voltammetry (FSCV) offers another method for measurement of brain analytes, 
specifically electro-active species in the brain such as dopamine. Carbon fiber microelectrodes (7 
µm in diameter) are most commonly used for detection. Compared to microdialysis, temporal 
resolution is superior with microelectrodes as it can detect real-time (ms) neurological events. 
Microelectrodes are much less invasive than microdialysis probes therefore providing better 
spatial resolution. Acute studies with microelectrodes in the rat striatum displayed minimum 
damage at the implantation site by light and electron microscopy.28 Fluorescence microscopy 
revealed no blood vessel disruption and an absence of gliosis 24 hours after microelectrode 
implantation.18 
FSCV achieves dopamine detection by applying a triangular waveform potential to a 
microelectrode at a fast scan rate (400 V/s) every 400 ms. A fast scan rate allows for excellent 
selectivity. The potential is ramped from 0 to 1 V, then from 1 to -0.5 V, then back to 0 V. 
Dopamine is oxidized to dopamine-o-quinone at 0.7 V and reduced back to dopamine at -0.2 V. 
Oxidization and reduction occurs at the surface of the electrode. The current generated can be 
converted into dopamine concentration via post-calibration of the electrode in a flow cell. 
There is a discrepancy between resting dopamine concentrations measured by 
microdialysis and microelectrodes. Dopamine in dialysate is in the low nanomolar range.29 
Dopamine as measured by FSCV coupled with microelectrodes is 2 µM.30 Furthermore, probe 
implantation significantly alters stimulated (evoked) dopamine release in tissue surrounding 
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microdialysis probes. Probes completely abolished evoked dopamine release at microelectrodes 
directly adjacent to probes. Evoked dopamine release decreased 10-fold at microelectrodes 220-
250 µm away.29 This implies that probe implantation alters the dopaminergic system at least 220-
250 µm away from probes. 
Nomifensine, a DAT uptake inhibiter, revived evoked dopamine release near probes in 
the striatum.29, 31 After nomifensine, evoked dopamine release returned at microelectrodes 
adjacent to microelectrodes and increased evoked dopamine release 220-250 µm from probes.29 
A combination of raclopride (D2 dopamine receptor antagonist) and nomifensine increased 
evoked dopamine release 200 µm from probes by 50 % of its pre-probe response.31 This suggests 
that at least 50 % of dopamine terminals survive probe implantation. 
1.1.5 Present Work 
We used carbon fiber microelectrodes coupled with FSCV to monitor evoked dopamine release 
in the rat striatum in two distinct projects. First, chapters 2, 3, 4, and 5 focus on mitigation of 
microdialysis probe induced damage and preservation of dopamine and potassium in surrounding 
brain tissue. We hypothesize that microdialysis probe implantation suppresses dopamine 
terminals and that reducing the cellular damage and ischemia triggered by probe implantation 
will allow dopamine terminals to function on a more normal level. In chapter 2, the effect of 
probe implantation on evoked dopamine release near (70-100 μm away) microdialysis probes is 
examined. Pharmacological agents dexamethasone and XJB-5-131, a reactive oxygen species 
scavenger, increased blood flow, neurons, and dopamine terminals causing increased evoked 
dopamine responses in tissue near the probe.32 Chapter 3 illustrates dexamethasone’s ability to 
preserve evoked dopamine responses near probes for 24 hours. Dexamethasone effects are 
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limited to the tissue directly surrounding the probe. Probe implantation with and without 
dexamethasone had no effect on dopamine terminals themselves at 24 hours.33  This implies that 
dexamethasone’s actions are anti-inflammatory in nature and do not act on dopamine terminals. 
Chapter 4 exemplifies other anti-inflammatory agents and reactive oxygen species scavengers 
that improve evoked dopamine responses in tissue near probes. In Chapter 5, potassium ion 
selective microelectrodes were used in a preliminary study investigating microdialysis probe 
implantation on the ability to measure potassium changes in surrounding tissue. 
Second, Chapter 6 investigates the relationship between the heterogeneity of evoked 
dopamine release and patch-matrix striatal compartments. Patch-matrix compartments in the 
striatum receive different dopamine inputs. In this study, the medial and lateral sub-regions of 
the striatum were found to be distinct with respect to dopamine kinetic diversity. Fast releasing 
dopamine domains dominate the lateral striatum where as slow releasing dopamine domains 
were abundant in the medial striatum. We also report strong evidence that fast domains 
correspond to patch compartments and slow domains to matrix compartments. 
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2.0  PHARMACOLOGICAL MITIGATION OF TISSUE DAMAGE DURING BRAIN 
MICRODIALYSIS 
The contents of this chapter were previously published in:  Nesbitt, K.M., Jaquins-Gerstl, A., 
Skoda, E.M., Wipf, P., Michael, A.C. Anal. Chem. 2013, 85, 8173-8179. 
I would like to acknowledge that the immunohistochemistry work in this chapter was performed 
by Andrea Jaquins-Gerstl. 
2.1 INTRODUCTION 
Microdialysis sampling is used extensively in the chemical analysis of brain tissues in animals 
and, in some cases, human patients.8-10, 34  Microdialysis offers several advantages for in vivo 
studies because the dialysis membrane eliminates cellular debris, blood, and macromolecules 
from the sample stream, which might otherwise clog or damage analytical systems.  This affords 
a high degree of flexibility in the coupling of analysis techniques to the sampling probes.  
Furthermore, the probes collect essentially all substances below the membrane’s molecular 
weight cutoff, which varies depending on the type of membrane.35  For these reasons, 
applications of brain microdialysis are very broad and continue to expand.5, 35-38  Increasing the 
spatial resolution and temporal response of microdialysis sampling is a recent development, with 
temporal response approaching the timescale of a few seconds in some cases.1, 39-40 
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 Despite its several advantages, brain microdialysis suffers from a persistent and 
challenging problem stemming from the wound that is caused when the probes are inserted into 
brain tissues.14-18, 26  Typical probes have a diameter of 220 μm or more, whereas the typical 
spacing between blood vessels in brain tissue is around 60 μm.28  Consequently, implanting a 
microdialysis probe damages blood vessels and causes ischemia in the surrounding tissue.17-18  
The penetration injury activates the brain’s astrocytes, which engulf the probe and eventually 
form a glial scar around it: scar formation is clearly evident 5 days after implanting the probe.26  
Microglia, a second class of brain glial cell, respond to a penetration injury within a few 
minutes.41 
 The penetration injury results in a progressive disruption of the tissue adjacent to the 
probe.  For example, Holson et al. described progressive declines in the response of dopamine 
(DA), a neurotransmitter, to several pharmacological challenges (methamphetamine, bupropion, 
haloperidol, and potassium ion) at 2, 4, and 6 h after implanting the probe.42-43  The declines 
depended only on the time since probe implantation and not the type or sequence of the 
manipulations: the authors concluded that a progressive loss of DA activity occurs in the tissue 
surrounding the probe.  We reached the same conclusion by ‘voltammetry next to microdialysis 
probes’.  We used a carbon fiber microelectrode to record DA release in the rat striatum during 
electrical stimulation of the afferent DA pathway.  Implanting a microdialysis probe next to the 
microelectrode either attenuated or abolished the DA response, providing a direct observation of 
a progressive decline in DA activity adjacent to the probe.29, 31 
 Penetration injury is not unique to microdialysis probes and is a matter of concern also in 
the case of neuron recording electrodes, such as those used for brain-machine interfaces.11-13  A 
number of laboratories have examined the effects of protective drugs, including dexamethasone, 
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on the tissue response to neuron recording electrodes.20-23, 44  Likewise, in a subcutaneous 
microdialysis study, dexamethasone suppressed the immune response to probes.25  Motivated by 
these positive findings, we investigated the retrodialysis of dexamethasone, a potent anti-
inflammatory and immunosuppressant glucocorticoid, into the rat striatum.  Dexamethasone 
exhibited a profound ability to restore blood flow and suppress gliosis but only negligibly 
affected DA microdialysis results.26  It is possible that the DA results are mainly dependent on 
the state of the brain tissue immediately adjacent to the probe, where the penetration injury is 
likely at its most severe.26  The goal of the present study was to investigate the consequences of 
the retrodialysis of protective compounds while using voltammetry to measure DA a short 
distance away from the probe (70-100 μm, see Methods), i.e. at a location where the penetration 
injury is possibly less severe and thus more amenable to mitigation but also sufficiently close to 
the probe for effective drug delivery via retrodialysis. 
 We used voltammetry next to microdialysis probes to record electrically evoked DA 
release in the rat striatum during the retrodialysis of dexamethasone (DEX) or XJB-5-131 (XJB).  
Whereas DEX is an anti-inflammatory drug, XJB is a reactive oxygen species (ROS) scavenger 
targeted with high selectivity to mitochondria.45-47  Recent studies show that XJB decreases lipid 
oxidation and improves neurocognitive function in rats after traumatic brain injury.48  Based on 
these observations, we hypothesized that XJB might also mitigate penetration injury.  We further 
hypothesized that XJB might be particularly effective at protecting DA axons and terminals, 
which are highly sensitive to oxidative stress and mitochondrial dysfunction.49-50  Following 
voltammetry next to the microdialysis probe, brain tissue containing the probe track was 
examined by fluorescence microscopy using markers for ischemia (fluorescent nanobeads), 
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neuronal nuclei (Neu-N), blood born macrophages (ED-1), and DA axons and terminals (tyrosine 
hydroxylase, TH). 
2.2 EXPERIMENTAL SECTION 
The procedures used herein have been employed in several prior studies.17-18, 26, 29, 31  Therefore, 
only key aspects are described here and additional details are provided as Supplementary 
Information. 
2.2.1 Reagents and Solutions 
Artificial cerebrospinal fluid (aCSF: 142 mM NaCl, 1.2 mM CaCl2, 2.7 mM KCl, 1.0 mM 
MgCl2, 2.0 mM NaH2PO4, pH 7.40) was used for voltammetric DA calibration and as the 
perfusion fluid for microdialysis. Dexamethasone sodium phosphate (APP Pharmaceuticals LLC, 
Schaumburg, IL) and nomifensine maleate (Sigma Aldrich, St. Louis, MO) were used as 
received from their respective suppliers.  XJB-5-131 was prepared as described by Wipf and 
coworkers.45  For retrodialysis, DEX (7.6 μM) and XJB (10 μM) were dissolved in aCSF and 
aCSF containing 1% DMSO, respectively (we lowered the concentration of DEX slightly 
compared to our previous study during which an adverse reaction to DEX was observed;26 the 
XJB concentration used here is near the solubility limit in 1% DMSO).  Nomifensine was 
dissolved in phosphate-buffered saline (PBS: 155 mM NaCl, 100 mM NaH2PO4, pH 7.40) and 
administered at 20 mg/kg (i.p.). All solutions were prepared with ultrapure water (Nanopure; 
Barnstead, Dubuque, IA). 
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2.2.2 Voltammetry and Microdialysis 
DA was measured in vivo by fast scan cyclic voltammetry (FSCV) with carbon fiber 
microelectrodes (7 µm in diameter, 400 µm in length). Concentric-style microdialysis probes 
(300 μm in diameter, 4 mm in length) were built in-house using membranes with a 13 kDa 
MWCO (Spectra/Por hollow fiber, Spectrum Laboratories Inc., Rancho, Dominquez, CA).  The 
probe inlet tubing (PE-20) was connected to a syringe pump (Harvard Apparatus, Holliston, MA) 
running at 0.610 µL/min.  The probe outlet tubing (fused silica) was led to waste: the dialysate 
fluid was not analyzed during this work. 
2.2.3 Voltammetry Next to a Microdialysis Probe 
All procedures involving animals were approved by the University of Pittsburgh’s Animal Care 
and Use Committee.  Voltammetry next to a microdialysis probe was performed in three groups 
of rats (n=6 rats per group).  Each group underwent microdialysis with a different perfusion 
fluid: aCSF, aCSF with DEX (7.6 μM), or aCSF with XJB (10 μM and 1% DMSO: a fourth 
group was perfused with aCSF with 1% DMSO but the results are omitted because they were 
identical to those obtained with aCSF alone). 
A carbon fiber voltammetric electrode was inserted into the striatum of an anesthetized 
rat and a stimulating electrode was lowered into the DA afferent pathway in the medial forebrain 
bundle (MFB).  Electrically evoked release was recorded by FSCV during electrical stimulation 
of the MFB (stimulus waveform: biphasic, square, constant current pulses at 45 Hz, 300 μA 
pulse height, 2 ms pulse width, for 25 s).  At least three stimulus responses were recorded to 
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establish a stable, pre-probe response: at least 20 min intervals were inserted between stimulus 
procedures. 
Next, a microdialysis probe was implanted in the same coronal plane as the 
microelectrode.  The final position of the probe was such that the distance between the tip of the 
microelectrode and the surface of the probe was 70 μm and the distance between the top of the 
electrode and the probe was 100 μm (Figure 2.1).  The relative position of the devices described 
here is nominal: it is based on adjustments made to the stereotaxic micropositioners (10 μm 
resolution).  We relied on the nominal position because it is not possible to visualize the location 
of a carbon fiber track without making a lesion:18 the lesion destroys the tissue and would have 
prevented the immunohistochemical analysis described in the following section. 
Next, 2 h after implanting the probe, three more stimulus responses were recorded: this is 
now ‘voltammetry next to the microdialysis probe’.  Each rat then received a single dose of 
nomifensine (20 mg/kg i.p.), and a final stimulus response was recorded 25 min later. 
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Figure 2.1. A schematic of the placement of the devices in the rat brain. (a) A sagittal view of the stimulating 
electrode (orange) in the MFB, the microelectrode (black) and the microdialysis probe (red) in the striatum (CPu), 
and the Ag/AgCl reference electrode (blue) in contact with the brain surface.  (b) A coronal view showing the 
microelectrode at a 5° angle from the probe. (c) The tip of the carbon fiber is 70 µm from the probe and the top of 
the fiber is 100 µm from the probe. 
2.2.4 Tissue Fixation and Immunohistochemistry 
After recording the stimulus responses, the probe was left in place for a total of 4 h.  Then, the 
rats were systemically perfused through the heart with fixative followed by a suspension of 
fluorescent nanobeads (Invitrogen, Eugene, OR), after which the tissue was post-fixed.17-18  The 
brain tissue containing the microdialysis probe track was sliced in a cryostat and the sections 
were immunolabeled with antibodies for NeuN (Chemicon, Temecula, CA), ED-1 (AbD Serotec, 
Raleigh, NC), or TH (Millipore, Temecula, CA).51  The secondary antibody was goat anti-rabbit 
IgG-CY3 (Invitrogen, Eugene, OR). 
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2.2.5 Fluorescence Microscopy and Image Processing 
Fluorescence microscopy was performed with a 20X objective (Olympus BX61, Olympus; 
Melville, NY) and filter sets as appropriate for the nanobeads and IgG-CY3 (Chroma 
Technology; Rockingham, VT). Quantitative image processing was performed with 
Metamorph/Fluor 7.1 software (Universal Imaging Corporation; Molecular Devices) and 
OriginPro.  A threshold value was established to eliminate background light from each image 
and a freehand tool was used to exclude the track and adjacent edge effects from the region of 
interest (see Supplementary Information for additional details).  In the case of tissues labeled 
with nanobeads and anti-TH, the number of fluorescent pixels was expressed as a percentage of 
the total number of pixels in the region of interest (% fluorescent pixels).  In the case of tissues 
labeled with anti-NeuN and anti-ED-1, the number of labeled cells was counted and normalized 
with respect to the area of the region of interest (cells/mm2).  Please note: the procedure used 
here to quantify the images does not account for differences in the intensity (i.e. brightness) of 
the fluorescence: this is because the fluorescence intensity is influenced by several factors that 
are difficult to control, such as the scattering properties of the tissue section, the tissue 
penetration by the antibody and blocking reagent, the extent of photobleaching, the power of the 
laser, etc.  Statistical analyses of the fluorescent counts from the images obtained with aCSF, 
DEX, or XJB were based on ANOVA.  For comparison, images of non-implanted tissue 
obtained from the brain hemisphere opposite to the microdialysis probes were processed and 
counted in the same fashion: results from the opposite hemisphere were omitted from the 
statistical analyses, which were intended to assess the impact of perfusion conditions on the 
tissue at the probe tracks. 
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2.3 RESULTS AND DISCUSSION 
2.3.1 Electrically Evoked DA Release 
Before implanting the probe, electrical stimulation of the DA afferent pathway evoked robust 
DA release in the rat striatum (Figure 2.2, blue lines).  The solid lines in Figure 2.2 are the 
average DA concentration measured in each group of animals and the dashed lines are 
confidence intervals based on the SEM of each data point. 
2.3.2 Microdialysis Probes Disrupt Evoked DA Release 
In the case of microdialysis probes perfused with aCSF (i.e. no DEX, no XJB), implanting the 
probe next to the voltammetric electrode abolished all the electrically evoked DA responses.  DA 
was not detected during any of the electrical stimuli applied after implanting the probe.  Next, we 
gave the rats nomifensine (20 mg/kg i.p.), a DA reuptake inhibitor that increases the 
concentration of DA observed during electrical stimulation procedures.52-53  Stimulated DA 
release was observed after the dose of nomifensine (Figure 2.2a, green). 
The experiment in Figure 2.2a is similar, but not identical, to those reported previously 
by Borland et al. and by Wang and Michael.29, 31  In the current work, we placed the 
microelectrode 150 μm closer to the probe, so the responses in Figure 2.2 are smaller than those 
we reported before.  We decreased the spacing during this work in order to increase the 
likelihood that the microelectrode would be in the diffusion zones of DEX and XJB in the 
following experiments.  
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The response obtained after nomifensine administration (Figure 2.2a, green) has an 
interesting feature.  That is, the DA signal is detected right away when the stimulus begins, i.e. 
during the first FSCV scan performed 250 ms after the stimulator is activated.  Using the 
reported diffusion coefficient of DA in the rat striatum, 2.4x10-6 cm2/s,54 the average diffusion 
distance in 250 ms is ~11 μm.  Thus, the DA detected when the stimulus begins was released 
from DA terminals in close proximity to the microelectrode.  This supports a previous suggestion 
from our laboratory that some surviving DA terminals are present near the microelectrode, 
although they may be in a suppressed state.31  This motivates our on-going efforts to protect and 
preserve the activity of those surviving DA terminals. 
2.3.3 DEX and XJB Preserve Evoked DA Activity Next to Microdialysis Probes 
In the case of microdialysis probes perfused with DEX, implanting the probe next to the 
microelectrode diminished, but did not abolish, electrically evoked DA release (Figure 2.2b, 
red).  Thus, retrodialysis of DEX diminished the loss evoked DA activity, possibly indicating 
improved survival of DA terminals in the tissue near the probe.  To facilitate comparison with 
the results obtained using probes perfused with unmodified aCSF, we again recorded a stimulus 
response after treating the animals with nomifensine (Figure 2.2b, green): DEX substantially 
enhanced the amplitude of the post-nomifensine response.  Implanting probes perfused with XJB 
also had beneficial effects on evoked DA release: similarly to DEX, XJB diminished but did not 
abolish evoked DA release next to the microdialysis probe (Figure 2.2c, red), although XJB was 
less effective than DEX in this regard (and see Figure 2.3, below, for statistical evaluation). 
However, similarly to DEX, XJB substantially enhanced the amplitude of the post-nomifensine 
response (Figure 2.2c, green).  As was the case during aCSF perfusion, DA was rapidly detected 
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at the start of the stimulus after nomifensine administration, indicating the presence of surviving 
DA terminals in close proximity to the voltammetric microelectrode.  Overall, these results 
confirm that both DEX and XJB preserved DA activity in the tissue next to the microdialysis 
probes. 
Figure 2.2. The effect of aCSF (a), DEX (b), or XJB (c) on electrically evoked DA responses measured before 
implanting the probe (blue lines), 2 h and 40 min after implanting the probe (red lines, the response was non-
detectable in a), and 25 min after nomifensine (green lines). The solid lines are the average of the responses in each 
group of rats (n=6 per group) and the broken lines are confidence intervals based on the standard error of the mean 
of each data point. The black diamonds show when the stimulus begins and ends. 
2.3.4 Statistics 
To facilitate statistical analysis of these results, we prepared a histogram of the maximum DA 
response amplitudes normalized with respect to the maximum amplitude of the responses 
recorded before each probe was implanted (Figure 2.3).  In the case of perfusion with aCSF, no 
DA was detected before nomifensine administration.  Therefore, we used one-sample, one-tailed 
t-tests to compare the DEX and XJB (Figure 2.3, red bars) results to zero: both DEX and XJB 
significantly increased the evoked response amplitude.  The normalized nomifensine results 
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(Figure 2.3, green bars) were subjected to a one-way ANOVA and posthoc Tukey test.  Both 
DEX and XJB significantly increased the post-nomifensine response amplitude.  These findings 
demonstrate that perfusion with DEX or XJB preserves robust DA uptake activity in the tissue 
nearby the microdialysis probes.  This robust DA uptake activity likely contributed to keeping 
the pre-nomifensine amplitudes small.  The responses observed after uptake inhibition by 
nomifensine, therefore, more directly reflect the protection of DA release afforded by DEX and 
XJB.  Based on Figure 2,3, we conclude that both DEX and XJB significantly attenuate the loss 
of DA activity in the tissue near the microdialysis probes. 
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Figure 2.3. The amplitude of evoked DA responses in the rat striatum in the presence of probes perfused with aCSF, 
DEX, or XJB.  The response amplitudes observed after implanting the probes (red) and after nomifensine (green) are 
normalized with respect to the amplitude observed before implanting the probes (blue = 100%).  The bars show the 
mean ± SEM (n=6 rats per group) of the normalized results.  DEX significantly increased evoked DA after 
implanting the probe (one-sample t-test: t(5)=8.208, p<0.0005).  XJB significantly increased evoked DA after 
implanting the probe (one-sample t-test: t(5)=2.015, p<0.05).  Both DEX and XJB significantly increased evoked 
DA after nomifensine administration (one-way ANOVA: F(2,15)=7.43, p=0.006; and Tukey posthoc test: p<0.05. 
and p<0.05 respectively). *p<0.05, ***p<0.0005. 
2.3.5 DEX and XJB Mitigate the Histochemical Effects of Microdialysis Probes 
We used fluorescence microscopy to examine thin horizontal sections of brain tissue containing 
the tracks of the microdialysis probes perfused with aCSF, DEX, or XJB (Figure 2.4).  For 
comparison, Figure 2.4 includes images of non-implanted control tissue (taken from the brain 
hemisphere opposite to the microdialysis probe) immunolabeled in the same fashion as the probe 
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tracks.  As we have reported before, probes perfused with unmodified aCSF caused profound 
ischemia (diminished blood flow), as indicated by a near-total absence of fluorescent nanobeads 
in the tissues surrounding the probe tracks.17-18  Both DEX and XJB increased the presence of 
nanobeads near the probe tracks (see Figure 2.5, below, for statistical evaluation), indicating in 
both cases a decrease in ischemia.  However, DEX was more effective in this regard, which is 
consistent with DEX’s classification as an anti-inflammatory drug. 
Probes perfused with unmodified aCSF decreased NeuN labeling, indicating a loss of 
striatal neurons near the probes, and increased ED-1 labeling, indicating the infiltration and 
activation of macrophages near the probes.  The ED-1 marker specifically labels blood-derived 
macrophages and so indicates an opening of the blood-brain barrier.55  Both DEX and XJB 
increased NeuN labeling and decreased ED-1 labeling, indicating that both compounds protected 
the brain tissue near the probes. 
In non-implanted striatal tissue, TH labeling is punctate, corresponding to the size and 
distribution of DA axons and terminals.  Probes perfused with unmodified aCSF eliminated the 
punctate labeling in the surrounding tissue.  Intense labeling was observed at the edges of the 
probe track but this was not punctate and likely reflects non-specific binding.56  The loss of 
punctate TH labeling does not necessarily mean a loss of DA axons and terminals, but rather that 
the axons and terminals have lost their TH.  Despite this caveat, the images confirm that probes 
perfused with aCSF profoundly disrupt DA axons and terminals.  Both DEX and XJB 
diminished the non-specific edge effect and preserved punctate TH labeling. 
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Figure 2.4. DEX and XJB mitigate the histochemical impact of penetration injury.  Separate columns provide 
representative images of tissue after retrodialysis of aCSF, DEX, and XJB for 4 h.  The left-most column shows 
images of non-implanted control striatal tissue.  Separate rows provide representative images of tissue labeled with 
markers for blood flow (nanobeads), neuronal nuclei (NeuN), macrophages (ED-1), and dopamine axons and 
terminals (TH).  The probe track is in the center of the images and marked with an asterisk. Scale bars are 200 µm. 
22 
2.3.6 Statistics 
We quantified these images using Metamorph’s built-in tools.  After setting a threshold 
fluorescence intensity for each image, the software quantified the percentage of pixels exhibiting 
nanobead and TH fluorescence, and counted the number of NeuN-positive and ED-1-positive 
cells in the region of interest: the quantitative results are reported as histograms in figure 2.5.  
The numerical results for each marker were subjected to one-way ANOVA (details in the figure 
legend).  Compared to probes perfused with unmodified aCSF, retrodialysis of DEX significantly 
increased nanobead, NeuN, and TH labeling, and significantly decreased ED-1 labeling.  
Retrodialysis of XJB significantly increased NeuN labeling and decreased ED-1 labeling.  
Retrodialysis of XJB also increased nanobead and TH labeling, but these effects were not 
statistically significant. 
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Figure 2.5. Normalized counts of the individual histochemical markers were performed in the region of interest in 
horizontal tissue sections containing the track of the microdialysis probes. Nanobead (a) and TH (d) results are 
reported as the percentage of fluorescent pixels (mean± SEM).  NeuN (b) and ED-1 (c) results are reported as the 
number of cells/mm2 (mean± SEM). Statistical analyses were performed by one-way ANOVA and Tukey or 
Tamhane T2 post hoc tests: *p<0.05, **p<0.005, ***p<0.00005, ****p<0.00000005.  Images of non-implanted 
tissue from the brain hemisphere opposite the microdialysis probes were quantified by the same procedures (no-
probe) but omitted from the ANOVAs. 
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2.3.7 Correlation of Voltammetry and Immunohistochemistry 
Our findings reveal, for the first time, a general correlation between the ability of DEX and XJB 
to preserve DA activity as assessed by voltammetry next to microdialysis probes and their ability 
to protect the tissue near the probes as assessed by immunohistochemical labeling.  The most 
direct correlation can be expected between DA activity and punctate TH labeling, since DA 
activity derives from DA axons and terminals.  Figure 2.6 compares TH images with the DA 
responses taken from the same tissue: the white box in each image identifies the nominal 
location of the microelectrode.  Even from this small sampling, it is clear that the intensity of the 
punctate TH labeling near the probe correlates with the amplitude of the stimulus response.  Note 
that in the case of the probe perfused with unmodified aCSF, the bright TH labeling is non-
punctate: it is the non-specific edge effect explained above. 
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Figure 2.6. Correlation of voltammetry next to a microdialysis probe with TH immunohistochemistry.  Individual 
DA responses recorded after implanting the probe (without nomifensine) are compared with the TH 
immunohistochemistry from the same rat.  The white box indicates the nominal position of the microelectrode. 
Columns represent retrodialysis of aCSF, DEX, and XJB for 4 h. Scale bars are 200 µm. 
2.4 CONCLUSION 
The present study confirms that retrodialysis of dexamethasone or XJB-5-131 mitigates 
penetration injury during brain microdialysis.  Both compounds protected striatal DA activity as 
assessed by voltammetry next to microdialysis probes and both also mitigated the histochemical 
effects of the penetration injury.  The general correlation between the effects of DEX and XJB 
on DA activity and observed histochemical changes is potentially significant, because reports on 
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the impact of neuroprotection strategies on the tissue responses to implanted devices are 
expanding rapidly.57-60 
The protective effects observed during this study were partial, as neither the evoked DA 
activity nor the histochemical attributes of the tissue near the probe were preserved in their 
normal, completely uninjured state.  Nevertheless, the mitigation observed during this study is 
substantially larger than during our previous observations of DA no-net-flux, which were 
negligibly affected by DEX.26  Thus, as we anticipated, the tissue even a small distance from the 
probe (70-100 μm) appears to be more amenable to protection by DEX and XJB.  However, it is 
important to appreciate that measuring DA via microdialysis is an especially challenging task 
due to DA reuptake, which rapidly removes DA from the extracellular space and limits how far it 
can diffuse.  This challenge is illustrated by the large impact of the DA reuptake inhibitor, 
nomifensine, on the evoked DA responses.  Accordingly, we conclude that even though DEX 
and XJB protected the tissue 70-100 μm from the probe, DA’s ability to diffuse across the gap to 
the microdialysis probe was constrained, as usual, by reuptake.  It is important to appreciate this 
point because microdialysis has applications to numerous other substances of interest that are not 
subject to such avid reuptake.  It will be of great interest in the future to examine the effect of 
DEX, XJB, and other candidates on the microdialysis of substances other than DA. 
Finally, this investigation focused on acute implants only 4 h in duration.  Tremendous 
interest in chronic implants exists as well, and in particular, XJB has demonstrated significant 
efficacy in long-term neuroprotective studies.61  We reason that any protective strategy must be 
effective during the acute phase of the implant in order to preserve the tissue into the chronic 
phases, i.e. cell death in the acute phase is unlikely to be reversible.  Accordingly, we envision 
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that successful acute mitigation is needed as a precursor to successful chronic mitigation of 
penetration injury effects. 
2.5 SUPPLEMENTARY INFORMATION 
2.5.1 Fast Scan Cyclic Voltammetry 
Carbon fiber microelectrodes were constructed by pulling borosilicate capillaries (0.58 mm I.D., 
1.0 mm O.D., Sutter Instruments, Novato, CA) to fine tips around a single carbon fiber (7 µm 
diameter, T650, Cytec Carbon Fibers LLC., Piedmont, SC) with a vertical puller (Narishing 
Tokyo, Japan). The tips were sealed with a low viscosity epoxy (Spurr Epoxy, Polysciences Inc., 
Warrington, PA) and cured overnight at 70 ºC. The exposed fibers were cut to a length of 400 
μm.  The capillaries were filled with mercury and a nichrome wire (Goodfellow, Oakdale, PA) 
was inserted to complete electrical contact.  Microelectrodes were pre-treated by soaking the tip 
in isopropyl alcohol (Sigma Aldrich, St. Louis, MO) containing carbon decolorizing (Fisher 
Scientific, Pittsburgh, PA) for one hour. 
Fast scan cyclic voltammetry was performed using a computer controlled potentiostat 
(EI-400, Ensman Instruments, Bloomington, IN) and CV Tarheels version 4.3 software (Michael 
Heien, University of Arizona, Tucson AZ). The potential was applied between a Ag/AgCl 
reference electrode and a carbon fiber working electrode. The potential was ramped at a scan rate 
of 400 V/s from 0 V to 1 V, then to -0.5 V, and then back to 0 V. Scans were performed at 2.5 
Hz. Dopamine (DA) oxidation peaks were monitored between 0.6 V and 0.8 V on the initial 
potential sweep. DA voltammograms were created by background subtraction. DA current was 
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converted to DA concentration by post-calibration of electrodes in a flow cell with at least three 
different concentrations of DA (Sigma Aldrich, St. Louis, MO) dissolved in nitrogen purged 
artificial cerebrospinal fluid (aCSF). 
2.5.2 Animal and Surgical Procedures 
All procedures involving animals were approved by the Institutional Animal Care and Use of 
Committee of the University of Pittsburgh. Male Sprague-Dawley rats (250-350 g) were 
intubated, anesthetized with isofurane (0.5 % by volume, Baxter Healthcare, Deerfield, IL), 
placed in a stereotaxic frame and wrapped in a heating blanket. The scalp was shaved and the 
skull was exposed. Three holes were drilled through the skull and the dura was carefully cut 
away to expose the brain. The incisor bar was adjusted so that the dorsal ventral measurements at 
lamda and bregma were no more than 0.01 mm apart (flat skull). 
Evoked DA release was measured with microelectrodes 70-100 µm away from probes. 
Electrical connection between the brain and a Ag/AgCl reference electrode was achieved by 
creating a salt bridge with a Kimwipe soaked in aCSF and placed in a plastic pipette tip. A 
microelectrode was implanted into the striatum at a 5° angle from the vertical (0.7 mm anterior 
from bregma and 5.0 mm below dura). A bipolar stimulating electrode (MS303-1-untwisted, 
Plastics One, Roanoke, VA) was lowered into the ipsilateral medial forebrain bundle (MFB, 4.3 
mm posterior from bregma, 1.2 mm lateral from midline, and 7.2 mm below dura) until evoked 
DA release was detected in the striatum. 
Evoked release was measured three times at 20 min intervals. A microdialysis probe 
perfused with aCSF, aCSF with dexamethasone (DEX) or aCSF with XJB-5-131(XJB) was 
lowered into the striatum over the course of 30 min in the same coronal plane as the 
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microelectrode (0.7 mm anterior to bregma, 2.5 mm lateral from midline, and 7 mm below dura). 
Two hours after implantation, stimulation of the MFB resumed at 20 min intervals. Nomifensine 
(20 mg/kg) was administered by intraperitoneal (i.p.) injection after the third stimulus and 
evoked release was measured 25 min later. 
2.5.3 Statistics 
Statistical analysis was performed with SPSS software. The statistical tests used for each analysis 
are explained in the results and discussion section. 
2.5.4 Tissue Processing and Immunohistochemistry 
The tissue was fixed by transcardial perfusion with 200 mL of 0.2 g/mL phosphate buffer saline 
(1x PBS:  155 mM NaCl, 100 mM phosphate, pH 7.40) followed by 250 mL of 4 % 
paraformaldehyde (PFA) and 50 mL of 0.1 % fluorescent nanobeads (Invitrogen, Eugene, OR). 
After the brains were removed, the tissue was postfixed for 2 h in 4 % PFA, soaked overnight in 
30 % sucrose at 4 °C for cryoprotection, and stored at -80 °C until sliced.  For TH staining, 
brains were postfixed for 24 h in cold 4 % PFA and then sectioned.  
Horizontal tissue sections (perpendicular to the probes) were cut at 30 or 40 µm using a 
cryostat. For NeuN and ED-1 labeling, the slides were stored at -20 °C, washed three times in 1x 
PBS, incubated with Triton X-100 in PBS for 15 min, washed in 0.5 % bovine serum albumin 
(BSA), and soaked in 2 % BSA for 45 min.  Then, the sections were incubated with antibody 
(NeuN or ED-1) for 1 h at room temperature, rinsed repeatedly in 0.5 % BSA, and incubated 
with the secondary antibody in 0.5 % BSA for 1 h at room temperature.  Sections were rinsed in 
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0.5 % BSA and 1x PBS.  For TH labeling, the sections were rinsed multiple times in 1x PBS at 
room temperature for 1 h, incubated in a blocking solution containing 2 % BSA, 0.3 % Triton X-
100 in 1x PBS for 1 h at room temperature.  Free floating sections were incubation with the TH 
antibody in the blocking solution at room temperature for 2 h followed by incubation at 4 ⁰C for 
48 h.  Sections were rinsed three times for 10 min each in 1x PBS and incubated with the 
secondary antibody in blocking solution for 1 h at room temperature. Sections were then covered 
with gelvatol mounting medium (polyvinyl alchohol, gycerol, Tris buffer pH 8.5, and sodium 
azide in water) and coverslipped. 
2.5.5 Image Processing and Quantification 
As explained in the main text (see Fluorescence Microscopy and Image Processing), normalized 
counts of the four histochemical markers were obtained from images after the images were 
treated with a threshold to eliminated scattered light and after the use of a freehand graphics 
cursor to eliminate the probe track and its edges (in the case of tissues labeled for TH) from the 
region of interest.  Figure S2.1 illustrates these procedures by means of an example. Figure S2.1a 
is a raw image (not yet processed) of tissue surrounding a microdialysis probe track labeled with 
a primary antibody for tyrosine hydroxylase and a secondary antibody tagged with CY3.  Note 
that the entire image is at least slightly red, including the center of the probe track that contains 
no tissues.  This pale red background is due to light scattering.  The first step in image processing 
is to set a threshold value to eliminate the background (Figure S2.1b):  setting the threshold is a 
built-in function in Metamorph.  Once the user has set the threshold intensity, the software turns 
off any pixel with a subthreshold intensity value.  This removes the pale background (note in 
Figure S2.1b that the center of the probe track now appears black) but does not affect other 
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features of the image.  Figure S2.1c shows a line drawn by means of a freehand graphics cursor 
tool in the software package.  This line is placed around the probe track and its brightly labeled 
edges.  In TH-labeled images such as this, the edges of the probe track exhibited bright 
fluorescence but this is most likely nonspecific binding.  Inspection of the edge feature at high 
magnification did not reveal the expect pattern of labeling of axons or terminals.  The software is 
then instructed to define the region of interest as that portion of the image outside the freehand 
line.  Prior to counting, the software turns each pixel with an intensity above the threshold to 
white and leaves pixels with sub-threshold intensity black (Figure S2.1d).  The software then 
counts and reports the number of black and white pixels in the defined region of interest.  Note, 
this procedure reports just a count of the number of above-threshold pixels and does not attempt 
to account for variations in fluorescence intensity.  This is a typical approach to quantifying 
images such as these, because the fluorescence intensity can be affected by several factors, such 
has how well the antibody penetrates the tissue slice, etc., that are difficult to control from one 
image to the next. 
32 
Figure S2.1. Representative images of labeled brain tissue surrounding a microdialysis probe track.  The tissue has 
been labeled with primary antibody for tyrosine hydroxylase and secondary antibody tagged with CY3.  Images 
were processed using Metamorph software. The probe track is in the center of the each image. a) The raw image as 
imported into Metamorph. b) The same image after setting the threshold. c) The thin line was placed with a freehand 
graphics cursor.  The region of interest is the portion of the image outside the freehand line. d) Prior to counting, 
pixels above the threshold are set to white and pixels below the threshold are left black.  The software reports the 
number of white and black pixels in the region of interest. 
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3.0  MICRODIALYSIS IN THE RAT STRIATUM:  EFFECTS OF 24-HR 
DEXAMETHASONE RETRODIALYSIS ON EVOKED DOPAMINE RELEASE AND 
PENETRATION INJURY 
The contents of this chapter were previously published in:  Nesbitt, K.M., Varner, E.L., Jaquins-
Gerstl, A., Michael, A.C. ACS Chem. Neurosci. 2015, 6, 163-173. 
I would like to acknowledge that the immunohistochemistry work in this chapter was performed 
by Andrea Jaquins-Gerstl. 
3.1 INTRODUCTION 
Intracranial microdialysis has made multiple seminal contributions to our knowledge of the 
neurochemistry of the living brain.5, 8, 34, 62-72 The benefits and power of microdialysis for 
intracranial chemical monitoring, which are well known and have been reviewed often,35, 37, 73-79 
stem from the efforts of many laboratories to refine both the microdialysis probes and the 
instrumental methods used to analyze dialysate samples.4, 39, 80-83  There has been tremendous 
progress, for example, in lowering the detection limits for key substances, including 
neurotransmitters, which has in turn reduced sampling times and increased temporal 
resolution.36, 38, 84-86  Here, we wish to contribute to this on-going refinement effort by focusing 
attention on what happens when the probes are implanted into brain tissue. 
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Typical microdialysis probes, those in widespread use, have diameters of at least 250 
μm.37, 43, 87-88  Implanting these into the brain causes tissue damage, which in turn triggers a 
wound response.14-18, 26, 32, 89-94  The wound response involves a cascade of events, some of which 
begin right away and some of which develop over the course of several days.  Microglial cells 
respond within minutes to focal brain injury whereas astrocytes respond later.41, 95  Astrocytes 
form a scar around microdialysis probe tracks by 5 days post implantation.26  Probe implantation 
also causes ischemia, disruption of the blood brain barrier, and neuron loss.17-18, 26, 32  
Neurochemical instability over the post-implantation intervals has been reported as well.29, 31, 42-
43, 87, 96-98  Even so, the dialysate content of neurotransmitters exhibits sensitivity to 
tetrodotoxin,71 responds predictably to various drugs,80, 99-101 and correlates with behaviors.5, 35, 67, 
78, 102  These observations show that microdialysis provides valid and useful indices of 
neurochemical activity.  Nevertheless, evidence of neurochemical instability over the post-
implantation time window has been a long-standing issue in the field. 
We hypothesize that mitigating disruption of the tissue near the probes would continue 
the refinement of intracranial microdialysis.  To date, we have obtained encouraging results from 
the retrodialysis of dexamethasone (DEX), an anti-inflammatory drug, and XJB-5-131 (XJB), a 
novel scavenger of reactive oxygen species.32  During acute experiments conducted 2-4 hr after 
implanting microdialysis probes, both DEX and XJB diminished the loss in amplitude of evoked 
dopamine (DA) responses measured by fast-scan cyclic voltammetry (FSCV).  Histochemical 
studies provide clear indications that DEX and XJB offer anti-inflammatory protection of the 
tissues surrounding the probes.  Without DEX or XJB, the probes cause ischemia, disrupt 
endothelial cells, activate both astrocytes and microglia, and cause a loss in both neurons and 
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axons near the probe tracks.32  DEX was slightly more effective than XJB.32  DEX retrodialysis 
for 5 days prevented the formation of a glial scar.26 
We implanted microdialysis probes in the rat striatum for 4 and 24 hr, both with and 
without DEX in the perfusion fluid, and then measured evoked DA release next to probes with 
FSCV.  We report here for the first time that DEX significantly diminishes the loss in amplitude 
of evoked responses measured in the tissue next to the probe both at 4 and 24 hr after implanting 
the probes.  Surprisingly, DEX had no significant effect on two key tissue markers for dopamine 
terminals, tyrosine hydroxylase (TH) and the dopamine transporter (DAT): 24 hr after probe 
implantation, these markers were not significantly different than in control, non-implanted 
tissues.  We therefore attribute DEX’s effects on evoked dopamine responses next to 
microdialysis probes to its anti-inflammatory actions, as opposed to any direct actions on 
dopamine terminals.  Finally, we report for the first time that the penetration of DEX into the 
tissue near the probe is extremely limited.  Fluorescein-labeled DEX was found no further than 
80 μm from its delivery probe.  Moreover, DEX failed to abolish gliosis near a second probe 
placed 2 mm from the probe with DEX.  We therefore conclude that DEX’s anti-inflammatory 
actions are tightly confined to the immediate, local vicinity of the probe. 
3.2 EXPERIMENTAL SECTION 
The methods used during this study have been described previously.17-18, 26, 29, 31-32  We provide 
key details here and full descriptions in the Supporting Information document. 
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3.2.1 Reagents and Solutions 
All solutions were prepared with ultrapure water (Nanopure, Barnstead, Dubuque, IA).  All 
reagents were used as received from their suppliers. Artificial cerebrospinal fluid (aCSF: 142 
mM NaCl, 1.2 mM CaCl2, 2.7 mM KCl, 1.0 mM MgCl2, 2.0 mM NaH2PO4, pH 7.4) was the 
perfusion fluid for microdialysis. DEX sodium phosphate (DEX, APP Pharmaceuticals LLC 
Schaumburg, Il) was diluted to 10 μM in aCSF. This dose was used as we have previously 
observed a dramatic reduction in tissue disruption at 10 μM DEX for 24 hr.26 DEX fluorescein 
(DEX-FL, Life Technologies Grand Island, NY) was diluted to 10 μM in aCSF. Nomifensine 
maleate and S(-)-raclopride (+)-tartrate salts (Sigma Aldrich, St. Louis, MO) were dissolved in 
phosphate-buffered saline (PBS: 155 mM NaCl, 100 mM NaH2PO4, pH 7.40) and administered 
at 20 mg/kg (i.p.) and 2 mg/kg (i.p.) respectively.  Isopropyl alcohol (Sigma Aldrich, St. Louis, 
MO) and decolorizing carbon (Fisher, Pittsburgh, PA) were used to pre-treat carbon fiber 
electrodes for DA voltammetry.  DA (Sigma Aldrich, St. Louis, MO) standards were prepared in 
nitrogen-purged aCSF. 
3.2.2 Microdialysis Probes 
Concentric microdialysis probes (300 µm diameter, 4 mm length) were constructed with hollow 
fiber membranes (13 kDa MWCO, Specta/Por RC, Spectrum Laboratories Inc., Ranco 
Dominguez, CA). The inlet tubing (PE, Becton Dickinson, Franklin Lakes, NJ) was connected to 
a 1-mL gas tight syringe driven by a microliter syringe pump (Harvard Apparatus, Holliston, 
MA) at a rate of 0.610 μL/min. The outlet was a fused silica capillary (75 μM I.D., 150 μM O.D., 
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10 cm long; Polymicro Technologies, Phoenix, AZ).  Probes were perfused with either aCSF or 
aCSF containing 10 μM DEX. 
3.2.3 Microdialysis Probe Implantation 
All procedures involving animals were approved by the University of Pittsburgh’s Animal Care 
and Use Committee. Male Sprague-Dawley rats (250-350g; Hilltop, Scottsdale, PA) underwent 
sterile stereotaxic surgery under isoflurane anesthesia. The probes were lowered into the brain at 
5 μm/sec with an automated micropositioner (Model 2660, David Kopf Instruments, Tujunga, 
CA) and secured to the skull with screws and acrylic cement. Following surgery, the rats were 
placed in a Raturn Microdialysis Bowl (MD-1404, BASI, West Lafayette, IN) and the probes 
were perfused with aCSF or DEX for 24 hr. 
3.2.4 Voltammetry next to Microdialysis Probes 
Voltammetry next to microdialysis probes was performed in two groups of rats (n=6 rats per 
group). An additional control group (n=5) underwent an initial surgical procedure without probe 
implantation (a sham control). Four-hour maximum dopamine amplitudes previously collected43 
were used for probe temporal comparisons (Figure. 3.4 - 4 hr results). 
After spending 24 hr in the Raturn bowl the rats were anesthetized a second time and 
returned to the stereotaxic frame. A carbon fiber electrode (400 µm in length) was implanted in 
the same coronal plane as the probe.  As before,32 the electrode was implanted an angle of 5° 
from vertical so that it could be placed very close to the probe. At its final location, the tip of the 
carbon fiber was 70 μm and the base of the fiber (where it meets the tip of the glass capillary) 
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was 100 μm from the probe: we call this the E1 location (Figure S3.1).  A second carbon fiber 
was implanted vertically 1 mm posterior to and in the same sagittal plane as the probe: we call 
this the E2 location (Figure. S3.1). The relative position of the two carbon fibers to the probe is 
nominal:  it is based on the adjustments made using stereotaxic micropostioners (10 µm) 
resolution.32 
A stimulating electrode was lowered towards the MFB until evoked DA was detected at 
E2 (stimulus waveform: biphasic, square, constant current).  The parameters for subsequent 
stimuli are listed in the Results and Discussion section. 
3.2.5 Tissue Immunohistochemistry 
After the in vivo measurements, the rats were deeply anesthetized and the brain tissues were 
collected for immunohistochemical analysis.18  Thin horizontal sections (35 μm) were cut in a 
cryostat at -21 to -22°C and labeled together with antibody for tyrosine hydroxylase (TH; 
1:1000, Millipore, Temecula, CA) and the DA transporter (DAT; 1:400, Synaptic Systems, 
Göttingen, Germany). The secondary antibody was goat anti-rabbit IgG-Cy3 or IgG-Cy5 
(Invitrogen, Eugene, OR). In another group of rats, probes perfused with DEX-FL were 
implanted for 4 hr. Tissue processing details can be found the Supporting Information. In an 
additional group of rats, two probes were implanted 2 mm apart, one perfused with aCSF and the 
other perfused with DEX for 24 hr. Tissue sections (30 µm)  were then stained with antibodies 
for GFAP (BD Biosciences Pharmingen, San Diego, CA).  Fluorescence and optical differential 
interference contrast (DIC) images were acquired with an Olympus BX61 (Olympus; Melville, 
NY) equipped with a 20x objective. Non-implanted tissue (from the hemisphere opposite the 
microdialysis probe) was used as control tissue. Quantitative image analysis was performed with 
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NIS-Elements Advanced Research-version 4.00 software (Nikon Instruments Inc., Melville, 
NY). See Figure. S3.5 for further details. 
3.2.6 Statistics 
IBM Statistical Package for the Social Sciences (SPSS) 22 software was used for all statistical 
analysis. 
3.3 RESULTS AND DISCUSSION 
3.3.1 Characteristics of Evoked DA Release in the Rat Striatum 
Electrical stimulation of DA axons in the medial forebrain bundle (MFB) evokes DA release in 
the ipsilateral striatum, which is easily measurable by FSCV (Figure. 3.1a).103-106  We measured 
evoked dopamine responses both in the absence of microdialysis probes and with 
microelectrodes positioned 70-100 μm (E1) and 1 mm (E2) from the probes (Figure. S3.1).  In 
the absence of a microdialysis probe, there is no significant difference in the amplitude of evoked 
responses (45 Hz, 300 μA, 25 s) measured at the E1 and E2 locations (Figure. 3.1a and 3.2).  The 
24-hr sham control surgery (see Methods) had no significant effect on the response amplitudes 
measured at E1 (Figure. S3.2). 
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Figure 3.1. Evoked responses observed at the E1 (red) and E2 (blue) locations (a) with no microdialysis probe 
(n=5), (b) after 24 hr perfusion with aCSF (n=6), and (c) after 24 hr perfusion with DEX (n=6). The solid lines are 
the averages of the responses and the dotted lines are the SEMs.  The black diamonds show when the stimulus 
begins and ends (see Figure. 4.2 for statistics). 
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Figure 3.2. Summary of the amplitude of evoked responses (average ± SEM) at the E1 (red) and E2 (blue) locations 
without microdialysis probes (n=5) and 24 hr after probes were implanted and perfused with DEX (n=6).  The 
evoked response at the E1 location after perfusion with aCSF was non-detectable, so the aCSF results were excluded 
from the statistical analysis.  Statistical analysis was performed by two-way ANOVA with location (E1, E2, 
repeated measure) and probe (no probe, probe with DEX) as the factors.  Location is not a significant factor 
(F(1,9)=1.99, p > 0.05).  Probe is a significant factor (F(1,9)=9.08, p < 0.05).  Interaction between factors is 
significant (F=(1,9)=8.91, p < 0.05).  Post-hoc pairwise comparisons with Bonferroni corrections showed that in the 
presence of DEX the response amplitude at the E1 location is significantly smaller compared to the amplitude at E1 
with no probe (*** p  < 0.0005) and compared to the amplitude at E2 (*p < 0.05).  A separate one-sample t-test 
shows that the response amplitude at E1 after 24 hr of perfusion with DEX was significantly elevated above zero 
t(5)= 3.33, p < 0.05 (aCSF group). 
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3.3.2 Voltammetry Next to the Probes 
We report here for the first time that evoked responses at the E1 location are abolished 24 hr 
after implantation of microdialysis probes perfused with aCSF (Figure. 3.1b-red line).  This 
extends our prior acute study,32 which showed that evoked responses were abolished 4 hr after 
probe implantation.  Together, these findings support previous evidence of neurochemical 
disruption of the tissue near probes over the 4-24 hr post-implant interval,29, 31 when most 
microdialysis studies are performed.4, 37-38, 71 
We report here for the first time that retrodialysis of DEX for 24 hr diminishes, but does 
not eliminate, the loss in amplitude of evoked responses at the E1 location (Figure 3.1c-red line).  
Evoked responses at the E1 location were significantly elevated compared to zero response, 
although they were significantly smaller than the responses at the E2 location (Figure 3.2, 
statistics reported in the figure legend).  In the presence of DEX, there was no significant 
difference in the response amplitude at the E2 location compared to that observed in the absence 
of a probe (Figure 3.2).  Thus, DEX offers partial protection of evoked responses at the E1 
location without affecting the responses at the E2 location.  The lack of significant effects at the 
E2 location suggests that the tissue disruption is confined to the tissue in close proximity to the 
probe. 
DA reuptake affects the in vivo microdialysis recovery of DA90, 107-108  Therefore, it is of 
interest to know how inhibition of the DA transporter (DAT) affects evoked DA responses next 
to the probes.  Consistent with numerous reports in the absence of microdialysis probes,52-53, 109-
111 nomifensine (20 mg/kg i.p.) increased the amplitude of evoked DA responses at the E1 
location 24 hr after implanting the probes (Figure 3.3-green lines).  In the case of probes 
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perfused with aCSF, nomifensine elevated the evoked response from below to above the 
detection limit of FSCV (Figure 3.3). 
When probes were perfused for 4 or 24 hr without DEX, evoked DA responses at the E1 
location were non-detectable (Figure 3.4a).  Therefore, we must rely on responses measured in 
nomifensine-treated animals to compare the effects of DEX at 4 and 24 hr post-implantation 
(Figure 3.4b).   Statistical analysis was by 2-way ANOVA (details in the figure legend) with time 
(4 hr, 24 hr) and perfusion condition (aCSF, DEX) as factors with post-hoc tests.  The perfusion 
condition, but not time, was a significant factor (interaction was not significant).  Thus, DEX 
significantly affected the response amplitudes and those amplitudes were stable between 4 and 
24 hr post implantation. 
Figure 3.3. Nomifensine increases the amplitude of evoked responses at the E1 location (green = post-nomifensine, 
red = pre-nomifensine, responses in red are from Figure. 3.2; solid lines = response averages, dotted lines = SEMs, 
n=6 per group; black diamonds indicate where the stimulus begins and ends). 
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Figure 3.4. A summary of the amplitudes of evoked DA responses at the E1 location (average ± SEM) observed 4 
hr (pink)32 and 24 hr (orange) after probe implantation (a) before and (b) after administration of nomifensine.  In the 
absence of nomifensine, DA was non-detectable (ND) near probes perfused with aCSF: so, statistical analysis was 
confined to the results obtained after nomifensine administration (panel b).  Statistical analysis was by two-way 
ANOVA with time (4 hr, 24 hr), and perfusion condition (aCSF, DEX) as factors.  Time is not a significant factor 
(F(1,20)=2.22, p > 0.05).  The perfusion condition was a significant factor (F(1,20)=22.1, p < 0.0005).  The 
interaction between factors was not significant (F(1,20)=0.046, p > 0.05).  Post-hoc pairwise comparisons with 
Bonferroni correction show that DEX significantly increased the post-nomifensine responses at 4 and 24 hr 
compared to those observed with aCSF (** p < 0.005). 
3.3.3 Immunohistochemistry of the Probe Track 
We performed histochemical analysis of striatal tissues using antibodies for two widely accepted 
markers of DA terminals, tyrosine hydroxylase (TH) and the DAT.112-114  Non-implanted, control 
tissue (contralateral to microdialysis probes) exhibits punctate TH labeling (Figure 3.5 left).  
Punctate labeling is diminished in images of tissue near the tracks of probes perfused with aCSF, 
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which also exhibit diffuse TH labeling (Figure 3.5 middle): control experiments did not reveal 
non-specific binding, which indicates that the diffuse labeling is specific binding.  The exact 
cause of the diffuse labeling is unknown at this time but represents disruption of the tissue 
adjacent to the probe.  Punctate, but not diffuse, labeling is clearly visible in the image of tissue 
near the track of a probe perfused with DEX (Figure 3.5 right).  These images support the 
conclusion that DEX protects DA terminals near microdialysis probes. 
At lower magnification (Figure 3.6) control tissue labeled for TH and DAT exhibit non-
labeled areas corresponding to myelinated axon bundles, which are also visible under differential 
interference contrast (DIC).  The probe tracks are clearly visible (Figure 3.6, middle and bottom 
rows).  Some diffuse labeling around probes perfused with aCSF is evident in the TH image 
(Figure 3.6, middle row): we have observed such binding before and consider it an edge-effect.32, 
115  Overall, TH and DAT labeling was clearly evident near the tracks of probes perfused both 
with and without DEX (quantification is discussed, below). 
The intense TH labeling near probe tracks perfused with aCSF for 24 hr stands in clear 
contrast to the absence of TH labeling that we observed 4 hr after implantation.32  The exact 
mechanism whereby this interesting rebound of TH labeling occurs is not yet known: 
possibilities, to be explored further in future studies, might include the synthesis of new TH 
protein by surviving DA terminals and/or the sprouting of new DA terminals.116-117  The TH and 
DAT images were converted to 2D intensity scatter plots (Figure 3.7a), from which we 
determined Pearson’s Correlation Coefficient (PCC) and Manders’ Overlay Coefficient (MOC) 
(see the Supporting Information document for explanations of these coefficients).118  The 
correlation coefficients in images with and without probe tracks are indistinguishable for probes 
perfused with DEX (Figure 3.7b).  The correlation coefficients are only slightly reduced with 
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aCSF compared to DEX, most likely due to the non-specific edge effect.119  Overall, the probes 
with DEX had no significant effect on the correlation of TH and DAT labeling in the nearby 
tissue (see Figure 3.7 legend).  Regions of interest in the TH and DAT labeled images were 
defined to eliminate the probe track (for details, see Supplementary Information document 
Figure S3.3).  There were no significant differences in the quantitative TH and DAT labeling in 
non-implanted control tissue and the regions of interest around the tracks of probes perfused for 
24 hr with either aCSF or DEX (Figure 3.7c).  
Overall, probe implantation had no significant effect on TH and DAT, two key markers 
for DA terminals.  This supports our conclusion that DEX’s effects on evoked responses are 
attributable to its previously documented anti-inflammatory actions,26, 32 as opposed to direct 
actions on DA terminals.  Our prior studies show that DEX profoundly decreases ischemia, glial 
activation, and neuron loss in the tissues near microdialysis probes.26, 32  It appears that these 
actions are responsible for the effects of DEX on evoked DA responses next to microdialysis 
probes over the 4-24 hr post-implantation interval. 
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Figure 3.5. High magnification images (60X) of punctate TH labeling in control tissue (left), tissue near the tracks 
of probes perfused for 24 hr with aCSF (middle) and DEX (right).  Punctate TH labeling is diminished near probes 
perfused with aCSF and diffuse TH labeling is increased.  Control experiments did not indicate non-specific 
binding, so the diffuse labeling is presumed to derive from specific binding.   Punctate labeling is evident in the 
DEX image, which does not exhibit diffuse TH labeling.  The asterisk near the top of the middle and right hand 
images mark a portion of the probe track. 
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Figure 3.6. Separate rows illustrate representative fluorescent images of striatal tissue with no probe, or after 
retrodialysis of aCSF, or DEX for 24 hr. Separate columns provide tissue (from left to right) labeled with TH, DAT, 
their respective overlaid images and corresponding DIC images. Scale bars are 200 µm. 
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Figure 3.7. (a) Represents a scatterplot of TH and DAT intensities. (b) The correlation coefficients between TH and 
DAT pixels among the three groups (no probe, aCSF and DEX, n=3 rats (total of 6 images per group)) for both 
Mander’s Overlay (black) and Pearson’s Correlation (green). A two-way ANOVA comparing the treatment (no 
probe, aCSF, and DEX) and analysis (Pearson’s Correlation and Mander’s Overlay) showed that there were 
significant differences in treatment F(2,28)=14.2, p < 0.0001, analysis F(1,28)=29.7, p < 0.00001, and the 
interaction treatment*analysis F(2,28)=3.87, p < 0.05. A post-hoc Tukey test further showed aCSF correlation 
coefficients were significantly reduced compared to no  probe (p < 0.0005) and DEX (p < 0.0001). A post hoc 
pairwise comparisons with Bonferroni corrections showed that Mander’s Overlay and Pearson’s Correlation differ 
from each other with no probes (p < 0.05) and aCSF (p < 0.00005). (c) The average fluorescent intensity for TH 
(red) and DAT (blue) for no probe, aCSF and DEX (n=3 rats (total of 6 images per group)). Fluorescent intensity 
ranges from 0-255 with 255 being the highest value. In a two-way ANOVA comparing treatment (no probe, aCSF, 
and DEX) F(2,30)=0.97, p > 0.05 and stain (TH and DAT) F(2,30)=0.74, p > 0.05 there were no significant 
differences in average fluorescent intensity. 
3.3.4 Evaluating the Tissue Penetration and the Physical Extent of DEX’s Anti-
inflammatory Actions 
First, we used fluorescein-labeled DEX (DEX-FL) to assess how far DEX penetrates into the 
tissue near microdialysis probes.  After 4 hr of retrodialysis, DEX-FL penetrated only to 78.6 ± 
46.1 µm from the probe track (Figure 3.8).  This result, however, might be affected by the 
detection limit of the fluorescence measurement and possibly by loss of soluble DEX-FL during 
tissue processing.  So, second, we performed dual-probe microdialysis experiments (n=3) with 
the probes implanted 2 mm apart.  One probe was perfused with DEX for 24 hr, the other with 
aCSF.  DEX abolished gliosis, as measured with GFAP, near the probe with DEX but not near 
the probe 2 mm away (Figure 3.9).  We therefore conclude that DEX does not penetrate deeply 
into brain tissue and that its actions are confined to within close proximity to the delivery probe. 
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Figure 3.8. Images of the microdialysis probe track, from three different rats, after 4 hr perfusion of DEX-FL. DEX-
FL is delivered locally only to the tissue directly surrounding the probe. 
Figure 3.9. Fluorescently labeled GFAP images (a) with and (b) without DEX (b).  Retrodialysis was performed for 
24 hr in striatal tissue. The asterisks indicate the center of the probe tracks. 
3.4 CONCLUSION 
Our findings reiterate that tissue damage occurs when a microdialysis probe is implanted into 
brain tissue.14-18, 26, 32  The extent of damage is documented to be sufficient to cause time-
dependent neurochemical and histological disruptions in the tissue next to the probes over the 4-
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24 hr post-implant interval, a typical time frame for microdialysis studies.4, 37-38, 71  Here, based 
on the properties of evoked DA responses measured next to microdialysis probes and on 
histological findings, we have documented for the first time that DEX offers protective 
mitigation against such disruptions over the 4-24 hr time interval following probe implantation.  
The actions of DEX reported here appear to derive from its previously-documented anti-
inflammatory actions,26, 32 rather than any direct neurochemical action on DA terminals per se.  
We have also documented here a surprising rebound of TH labeling in the tissue surrounding 
probe tracks by 24 hr post-implantation: this might indicate the presence of surviving DA 
terminals, which justifies our efforts to protect and preserve their neurochemical activity.  
Finally, we document here for the first time that the actions of DEX are tightly confined to the 
immediate, local vicinity of the microdialysis probe used for delivery. 
3.5 SUPPLEMENTARY INFORMATION 
3.5.1 Fast Scan Cyclic Voltammetry 
Carbon fiber electrodes were constructed by threading a single carbon fiber (7 µm diameter, 
T650, Cytec Carbon Fibers LLC., Piedmont, SC) through borosilicate capillaries (0.58 mm I.D., 
1.0 mm O.D., Sutter Instruments, Novato, CA). The capillaries were pulled to fine tips around 
the carbon fiber with a vertical puller (Narishing Tokyo, Japan). Carbon fibers were glued in 
place with a low viscosity epoxy (Spurr Epoxy, Polysciences Inc., Warrington, PA) and cured 
overnight at 70 ºC. The exposed carbon fiber was cut to a length of 400 µm for in vivo studies or 
800 µm for detection at the outlet of microdialysis probes. Capillaries were backfilled with 
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mercury and a nichrome wire (Goodfellow, Oakdale, PA) was placed into the mercury to make 
an electrical connection. 
Fast scan cyclic voltammetry (FSCV) was executed using a computer controlled EI-400 
potentiostat (Ensman Instruments, Bloomington, IN) with CV Tarheels version 4.3 software 
(Michael Heien, University of Arizona, Tucson AZ). A triangular waveform was applied as a 
linear sweep (vs Ag/AgCl) from 0 V to 1 V, then to -0.5 V, and then back to the resting potential 
of 0 V at a scan rate of 400 V/s. Scans were performed at a frequency of 2.5 Hz unless otherwise 
noted. Background subtracted voltammograms were used to quantify dopamine (DA) on the 
initial potential sweep between 0.6 V and 0.8 V.  The DA current was converted to 
concentrations by post-calibrations with freshly prepared standard solutions of DA (Sigma 
Aldrich, St. Louis, MO) dissolved in nitrogen purged aCSF. 
3.5.2 Surgical and Stimulation Procedures 
All procedures involving animals were approved by the Institutional Animal Care and Use of 
Committee of the University of Pittsburgh. Male Sprague-Dawley rats (250-350 g, Hilltop, 
Scottsdale, PA) were anesthetized with isoflurane (0.5 % by volume, Henry Schein Animal 
Health, Elizabethtown, PA). Rats were wrapped in a heating blanket (37°C) and placed in a 
stereotaxic frame. The incisor bar was adjusted so the dorsal ventral measurements at lambda 
and bregma were no more than 0.01 mm apart (flat skull). For all voltammetry experiments, the 
reference and stimulating electrodes were placed in the same positions in the brain. Reference 
electrodes were connected to the brain via a salt bridge. Bipolar stimulating electrodes were 
lowered into the medial forebrain bundle (MFB) until maximum DA release was observed (4.3 
mm posterior and 1.2 mm lateral from bregma). Electrically evoked DA release was recorded by 
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FSCV during stimulation of the MFB (stimulus waveform: biphasic, square, constant current 
pulses 300 μA pulse height, 4 ms pulse width). 
3.5.3 24 hr Microdialysis Probe Implantation Procedure 
A small craniotomy was made over the striatum. Microdialysis probes were perfused with aCSF 
or DEX using a syringe pump. Probes were lowered slowly (5 µm/sec) into the striatum (1.6 mm 
anterior and 2.5 mm lateral from bregma) over the course of approximately 23 min using a 
micropositioner (Model 2660, David Kopf Instruments, Tujunga, CA) to final position of 7 mm 
below dura. Probes were secured with bone screws and acrylic cement. Anesthesia was removed 
and animals were placed in a Raturn Microdialysis Bowl Stand-Alone System (MD-1404, BASI, 
West Lafayette, IN) for one day. 
3.5.4 Electrode Placement for Voltammetry Next to Microdialysis Probes after 24 hr 
After 24 hr animals were re-anesthetized and placed back in the stereotaxic frame. Without 
disturbing the probe, holes were drilled for the reference electrode, stimulating electrode and 
both carbon fiber electrodes. One electrode (E1) was implanted lateral to the probe so that the tip 
of the carbon fiber was 70 µm and the base 100 µm from the probe. The second electrode (E2) 
was implanted 1 mm posterior to the probe (0.45 mm anterior from bregma, 2.5 mm lateral from 
midline, and 5 mm below dura). A stimulating electrode was placed into the MFB and evoked 
DA was recorded (Figure S3.1). 
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3.5.5 Fluorescent Dexamethasone Procedure 
Microdialysis probes were implanted for 4 hr during which dexamethasone fluorescein (10 µM) 
was perfused through the probe (n=3 rats). Horizontal sections (30 µm) were taken along the 
probe tract (130 slices per rat). Three random sections from each rat were imaged, thresholded 
and masked. Using NIS Element Advanced Research software random line measurements were 
perform in the area defined as a positive fluorescent signal. Nine different line measurements 
were made from each image for a total of 81 measurements. 
3.5.6 Defining TH and DAT Colocalization 
Fluorescence microscopy was used to examine the colocalization of tissue labeled for tyrosine 
hydroxylase (TH) and dopamine transporters (DAT). For each probe track, images of both TH 
and DAT were collect using sequential mode, allowing for images to be merged and a composite 
image created. Since it is difficult to visualize the degree of colocalization from a pair of images, 
an important alternative is to display the intensities of the pairs of homologous pixels in a 2D 
scatterplot. The two antibodies were analyzed for the degree of colocalization by measuring the 
equivalent pixel position in each of the acquired images by generating a 2D-scatterplot (Figure 
3.7a). Each axis covers the range of intensities of the fluorophores, in our case Cy3 and CY5 
(respectively, TH and DAT). The scatterplot shows the frequency of occurrence between the pair 
of intensities which reveals any correlation between the fluorophores. The relationship between 
the intensities in the two images is calculated by linear regression. The slope of this linear 
approximation provides the rate of association of the two fluorophores.120 Following the 
generation of the scatterplot it is possible to quantitatively evaluate colocalization between the 
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fluorophores (TH and DAT). Values calculated for the scatterplot using NIS Element Advanced 
Research software include Pearson’s Correlation Coefficient (PCC), and Manders’ Overlap 
Coefficient (MOC). Pearson’s Correlation and Manders’ Overlap are mathematically similar 
differing in the use of either absolute intensities (Manders’) or the deviation from the mean 
(Pearson’s).120-121 Pearson’s Correlation is well defined and is an accepted means for describing 
overlap between image pairs. It’s computed values are between -1 to 1 with -1 being no overlap, 
1 being perfect overlap and 0 representing random distributions between images. Only the 
similarities of shapes between images are account for not their intensities. PCC is defined as:122-
123 
 
where Ri= intensity in red channel, = average intensity in red channel, Gi= intensity in green 
channel and = average intensity in green channel. 
MOC is also used to describe overlap however this method does not perform any pixel 
averaging functions like that of PCC therefore values range from 0 to 1. This method is also not 
sensitive to intensity variations between images. MOC is defined as:122 
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3.5.7 Thresholding Images 
Specifying correct threshold limits is a crucial procedure for image analysis. The point is to 
determine which pixels will and will not be included in the analysis, therefore distinguishing 
pixels to be analyzed from background. Figure S3.3 illustrates this procedure by means of an 
example. In the center of each image is the probe track, each channel corresponds to a specific 
antibody (red=TH and blue=DAT), and the far right column is the overlay of both channels. The 
top row (a) is unprocessed raw data, certain pixels in this row appear very bright (especially 
toward the center around the probe track) and other pixels are very dim. The build in “smart 
threshold function” of the NIS Element Advanced Research software automatically disregards 
these pixels and applies a mask to only the pixels to be used in the analysis. In our case, the mask 
is colored in white (bottom row (b)). Since all the images are imported into the software at the 
same time they are batch processed thereby allowing for all images to be analyzed in the same 
manner avoiding user bias. 
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Figure S 3.1. Device placement in the brain after 24 hr probe implantation for evoked DA detection next to probes. 
(a) Represents a sagittal brain slice illustrating the microdialysis probe (red) expanding the length of the dorsal 
striatum. The reference electrode (blue) was in contact with the surface of the brain, a stimulating electrode (orange) 
was positioned in the medial forebrain bundle. E2 was implanted 1 mm posterior to the probe and E1 was implanted 
at a 5° angle 70-100 µm lateral to the probe. (b) Top-down view of device placement. 
Figure S 3.2. Maximum average (±SEM) evoked DA measured in two separate groups of rats during only one 
surgery (white) and after a second surgery (black). There was no significant difference in maximum evoked DA 
release after the second surgery t-test: t(9)=0.15, p>0.05. 
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Figure S 3.3. Example of the thresholding process by NIS Element Advanced Research software. The brain tissue 
contains a probe track in the center of each image. Columns represent individual channels. The last column is 
overlaid channels of the red and blue. Row (a) represents raw images and row (b) is the images after thresholding. 
Only the area in white is used in analysis. Pixels outside this region are not considered as they are either over or 
under the threshold limit. 
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Figure S 3.4. Labeling scheme of striatal tissue. (a) Horizontal slices cut 30 µm thick. (b) and (c) are representative 
images of tissue stained with TH and DAT antibodies and the corresponding overlay. (b) Indicates the edge of the 
striatum showing that only the striatum is stained with these antibodies. (c) Also includes the differential 
interference contrast image (DIC). Scale bars are 200 µm. 
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4.0  EFFECTS OF ANTI-INFLAMMATORY AND REACTIVE OXYGEN SPECIES 
SCAVENGERS ON MICRODIALYSIS PROBE PENETRATION INJURY IN THE 
BRAIN 
4.1 INTRODUCTION 
Microdialysis is a powerful analytical technique used to recover analytes from the extracellular 
space of the brain (neurotransmitters, metabolites, amino acids, neuropeptides).8, 34-35, 66, 69, 71, 84, 
124 Microdialysis probes consist of inlet tubing that leads to a semi-permeable membrane at 
which analytes diffuse across the membrane and are collected through outlet tubing. This simple 
technique can be coupled to various analytical methods (high-performance liquid 
chromatography, mass spectrometry, capillary electrophoresis) for simultaneous detection of 
small molecules. Commonly used probes are 200-300 µm in diameter. Implantation of probes 
into the brain damages the surrounding tissue decreasing blood flow, neurons and increasing 
microglia and astrocytes.14, 17-18, 26, 32-33 This penetration injury causes a progressive decline in 
dopamine (DA) an important neurotransmitter often studied using microdialysis.29, 33, 42-43, 97 
Specifically, probe implantation significantly decreases evoked DA release in the surrounding 
tissue.32-33 Although, DA terminals survive probe implantation, they do not seem to function on a 
normal level in tissue surrounding the probe.32-33 This often leads to in accurate sampling of the 
neurotransmitter, DA by microdialysis. 
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 Retrodialysis of dexamethasone (DEX), an anti-inflammatory steroid increases blood 
flow to the area surrounding the probe and reduces gliosis for at least 5 days.26, 32-33 By 
improving the health of the tissue DEX preserves neurons, DA terminals, and subsequently 
evoked DA release near probes at 4 and 24 hours.32-33 Pharmacological mitigation of probe 
induced tissue damage through the use of an anti-inflammatory provides a platform for 
improving long-term microdialysis. However, a concern with the steroid DEX is that it can cause 
negative side effects such as aggression and weight gain in animals and humans monitored by 
microdialysis. Steroids are also known to effect neurotransmission, some steroids acting 
specifically on the central dopaminergic systems.125-127 Therefore it is of important to investigate 
other non-steroidal anti-inflammatory agents and their ability to prevent tissue damage and loss 
of evoked DA release near probes. 
XJB-5-131, a reactive oxygen species (ROS) scavenger also partially prevented evoked 
DA loss near probes for 4 hours by improving overall tissue health.32 This particular ROS 
scavenger is unique in that it targets the inner mitochondrial membrane and contains a potent 
nitroxide group responsible for electron and radical scavenging.45 Although its effect on 
preserving evoked DA release was not as stunning as DEX’s, ROS’s neuroprotective qualities 
still make them good candidates for ‘pharmacologically enhanced microdialysis.’ 
The current study investigates the effects of two non-steroidal anti-inflammatories, 
ibuprofen (IBU) and pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid tetrasodium salt 
(PPads) and two ROS scavengers, JP4-039 (JP4) and JRS527 (JRS) on the preservation of 
evoked DA responses near microdialysis probes. As the effects of both DEX and XJB were 
profound after only 4 hours, this timeframe was used for the present study. Carbon fiber 
microelectrodes were coupled with fast scan cyclic voltammetry (FSCV) for detection of evoked 
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DA release in tissue near probes perfused separately with each pharmacological agent. Results 
were compared to evoked DA responses without pharmacological agent. 
4.2 EXPERIMENTAL SECTION 
4.2.1 Reagents and Solutions 
Dexamethasone sodium phosphate (DEX:  AAP Pharmaceruticals LLC, Schaumburg, IL), 
ibuprofen (IBU:  Sigma Aldrich, St. Louis, MO) pyridoxalphosphate-6-azophenyl-2',4'-
disulfonic acid tetrasodium salt (PPads:  Sigma Aldrich, St. Louis, MO), were used as received 
from their suppliers.  XJB-5-131 (XJB), JP4-039 (JP4), JRS527 (JRS) were prepared as 
described by Wipf and co-workers. All solutions were prepared with ultrapure water (Nanopure, 
Barnstead, Dubuque, IA). Artificial cerebrospinal fluid (aCSF: 142 mM NaCl, 1.2 mM CaCl2, 
2.7 mM KCl, 1.0 mM MgCl2, 2.0 mM NaH2PO4, pH 7.4) was used as the perfusion fluid for 
microdialysis. DEX, and PPads were diluted to 10 µM in aCSF, IBU, XJB, JP4, JRS were 
dissolved in aCSF containing 1% DMSO (Sigma Aldrich, St. Louis, MO). Nomifensine (20 
mg/kg, i.p., Sigma Aldrich, St. Louis, MO) was used as received. Nomifensine was dissolved in 
phosphate-buffered saline (PBS: 155 mM NaCl, 100 mM NaH2PO4, pH 7.40) for i.p. injections 
and diluted to 1 µM in aCSF for microdialysis perfusion. Electrodes were pre-treated in 
isopropyl alcohol (Sigma Aldrich, St. Louis, MO) and decolorizing carbon (Fisher, Pittsburgh, 
PA) Post-calibration of electrodes was performed with DA (Sigma Aldrich, St. Louis, MO) 
standards prepared in N2-purged aCSF. 
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4.2.2 Voltammetry and Microdialysis 
Carbon fiber microelectrodes (7 µm in diameter, and 400 µm in length) were coupled with fast 
scan cyclic voltammetry for in vivo measurement of evoked DA.29, 32-33 Concentric microdialysis 
probes (300 µm diameter, 4 mm length) were constructed in house as previously described with 
hollow fiber 13 kDa MWCO membranes (Specta/Por RC, Spectrum Laboratories Inc., Ranco 
Dominguez, CA).32 The probe inlet tubing (PE-20, Becton Dickinson, Franklin Lakes, NJ) was 
connected to a syringe pump (Harvard Apparatus, Holliston, MA) at a rate of 0.610 μL/min. The 
outlet made of fused silica capillary was led to waste as the dialysate fluid was not analyzed in 
this experiment. 
4.2.3 Voltammetry Next to Microdialysis Probes 
All procedures involving animals were approved by the University of Pittsburgh’s Animal Care 
and Use Committee. Male Sprague-Dawley rats (250-350g; Charles Rivers, Raleigh, NC) were 
anesthetized with isoflurane (2.5 % by volume) and placed in a stereotaxic frame. Voltammetry 
next to microdialysis probes was performed in six groups of rats (6 rats per perfusion fluid unless 
otherwise noted). 
A carbon fiber electrode was implanted at a 5 degree angle into the striatum of each rat. 
A stimulating electrode was lowered towards the medial forebrain bundle (MFB) until maximum 
evoked DA was observed at the carbon fiber electrode (4.3 mm below bregma, 1.2 mm lateral to 
bregma, and 7.2-8.5 mm below dura). Electrical stimulation of the MFB was performed for 25 s 
at 45 Hz (waveform:  biphasic, square, constant current, 300 µA) and evoked DA release was 
measured in the striatum in twenty minute intervals. 
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Once consistent evoked responses were observed, a microdialysis probe was slowly (over 
30 minutes) implanted next to the electrode (0.7 mm above bregma, 2.5 mm lateral from bregma, 
and 7 mm below dura).  In its final position, the microdialysis probe was 70 µm from the tip of 
the carbon fiber, and 100 µm from the base of the electrode (Figure 4.1a). The probe was left to 
perfuse in the brain for 2 hours. Following this, three more stimulus responses were recorded. 
Finally, nomifensine was administered (20 mg/kg i.p.) and one more stimulus response was 
collected. 
4.2.4 Data Analysis 
For comparison, evoked DA responses near probes perfused with only aCSF (no 
pharmacological agent) were used as the control. These results have previously been reported in 
Nesbitt et al 2013 and are presented in Figure 4.1b.32 For statistical analysis, all results were 
normalized with respect to the maximum amplitude of the responses recorded before probe 
implantation. Statistical analysis was performed using IBM Statistical Package for the Social 
Sciences (SPSS) 22 software. 
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Figure 4.1. (a) Schematic of microdialysis probe (left) and microelectrode (right) positions in striatum. (b) Average 
(±SEM) DA responses to a 25 s stimulation of the MFB recorded in the striatum pre-microdialysis probe 
implantation (blue), post-probe implantation (red), and post-probe, post-nomifensine (green). Microdialysis probes 
were perfused with aCSF (n=6 rats per agent). Solid lines represent the mean response and dotted lines the SEM. 
Black diamond indicate the beginning and end of stimulation. Data previously published.32 
4.3 RESULTS AND DISCUSSION 
4.3.1 Control Experiments 
In all of the following experiments evoked DA release was measured in the striatum during a 25 
s stimulation of the MFB. Responses measured pre-probe implantation showed robust maximum 
evoked DA release ranging from 12-20 µM (blue responses in Figure 4.1b, 4.3, and 4.5). As 
previously reported, microdialysis probes perfused with aCSF (no pharmacological agent) 
eliminated evoked DA release nearby (70-100 µm away). To determine if any DA terminals 
survived probe implantation, a competitive DA transporter inhibitor, nomifensine was 
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administered by i.p. injection. Nomifensine revived evoked DA release near probes. The 
immediate response to stimulation proves that DA terminals survive directly next to the 
electrode, no further than 70 µm from the probe.32 These results even though previously 
published are represented in Figure 4.1b for ease of reference.32 
4.3.2 Anti-Inflammatory and ROS Scavenger Agents 
This study compares the effects of three anti-inflammatory agents and three ROS scavengers’ on 
preserving evoked DA release in tissue surrounding microdialysis probes. DEX and XJB have 
previously been reported on,32 and are represented here for comparison purposes. The chemical 
structures of all pharmacological agents are represented in figure 4.2. The top panel illustrates 
the inflammatory agents and the bottom panel the ROS scavengers. 
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Figure 4.2. Top panel:  Chemical structures of anti-inflammatory agents. Bottom panel:  Chemical structures of 
reactive oxygen species scavenger provided by Wipf and co-workers.45 
4.3.3 IBU and Ppads Preserve Evoked DA Release Near Probes 
During an inflammatory event such as microdialysis probe implantation,14, 18, 26 cells up-regulate 
production of pro-inflammatory proteins causing activation of phospholipase A2. Through 
cyclooxygenase (COX) modification a cascade of inflammatory mediators are produced.128 Both 
DEX and IBU work to intervene at different stages of the inflammatory cellular mechanism. 
DEX acts by down-regulating pro-inflammatory proteins in cells and up-regulating anti-
inflammatory proteins produced by the cell.129 IBU is considered a COX-1 and COX-2 inhibitor 
thereby inhibiting COX modification and preventing inflammatory mediator signaling.130 
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The non-steroidal anti-inflammatory IBU, when perfused through microdialysis probes 
prevented complete loss of evoked DA release near probes (Figure 4.3-middle panel, red). 
Administration of nomifensine greatly impacted maximum evoked DA release near probes, 
increasing it to nearly pre-probe implantation amplitude (Figure 4.3-middle panel, green). IBU 
had similar effects as DEX suggesting that DEX’s effects on evoked DA release are due to both 
its anti-inflammatory actions, not steroidal actions on DA terminals. 
PPads is a non-selective P2 purinergic antagonist that blocks P2Y receptors. PPads 
reduces inflammation in the brain by blocking purine receptors on microglia limiting their 
response.41 Microglia are immune cells that are the first to respond to injury in the central 
nervous system. In a study investigating the migration of microglia, PPads significantly 
decreased the number and motility of the microglia responding to the site of an injury.41 PPads 
perfused through microdialysis also preserved evoked DA release near probes (Figure 4.3-right 
panel, red). Nomifensine further increased evoked DA release but not as dramatically as DEX 
and IBU (Figure 4.3-right panel, green). 
 For statistical analysis, maximum DA release was normalized with respect to the 
maximum amplitude of the responses recorded before each probe was implanted and presented 
in histograms (Figure 4.4, 4.6). As in the case of probe perfusion with aCSF, DA was undetected 
after probe implantation but before nomifensine, a one-sample t-test was performed comparing 
DEX, IBU, and PPads to zero. DEX, IBU, and PPads all significantly increased evoked DA 
release near probes (Figure 4.4a). DEX’s effect was more significant than IBU and PPads, and 
this is most likely due to DEX’s duel action to both decrease pro-inflammatory proteins and 
increase anti-inflammatory proteins. Post-nomifensine maximum evoked DA responses were 
subject to a one-way ANOVA. DEX, IBU, and PPads all significantly increased maximum 
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evoked DA release, DEX and IBU to above 80% of the pre-probe response. These findings 
demonstrate the ability of anti-inflammatories to preserve DA release and uptake activity in 
tissue near microdialysis probes. 
Figure 4.3. Average (±SEM) DA responses to a 25 s stimulation of the MFB recorded in the striatum pre-
microdialysis probe implantation (blue), post-probe implantation (red), and post-probe, post-nomifensine (green). 
Microdialysis probes were perfused with either DEX, IBU, or PPads (n=6 rats per agent). Solid lines represent the 
mean response and dotted lines the SEM. Black diamond indicate the beginning and end of stimulation. DEX data 
previously published.32 
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Figure 4.4. Effects of anti-inflammatory retrodialysis of agents on maximum evoked DA (a) post-probe 
implantation and (b) post-nomifensine. (a) As DA was non-detectable in the case of aCSF a one-sample t-tests was 
performed to compare each post-probe response to zero. DEX, IBU and PPads significantly increased maximum 
evoked DA compared to aCSF:  One-sample, one-tailed t-test:  DEX t(5)=8.21, ***p<0.0005, IBU 
t(5)=4.11,**p<0.005, PPads t(5)=3.46, *p<0.05. DEX is significantly different from IBU and PPads:  one-way 
ANOVA F(2,15)=5.20, p<0.05, Post-hoc tukey DEX is significantly different from IBU p<0.05, PPads p<0.05. (b) 
Post-nomifensine, DEX, IBU, and Ppads increased evoked DA compared to aCSF:   One-way ANOVA 
F(3,20)=7.28, p<0.005, Post-hoc tukey DEX:  **p<0.005, IBU:  **p<0.005, PPads:  *p<0.05. 
4.3.4 JRS Preserve Evoked DA Release Near Probes 
Inflammation is known to induce mitochondrial dysfunction and dopaminergic 
neurodegeneration in the nigrostriatal system.131 XJB infiltrates mitochondria, scavenging ROS 
thereby providing neuroprotection. XJB prevents neuronal loss and preserves evoked DA near 
probes.32 Wipf and co-workers developed a smaller analog of the XJB, JP4, to increase 
accumulation in mitochondria making the analog more potent. JP4 specifically targets 
72 
mitochondria, similar to XJB catalyzing the dismutation of superoxide radical anions and other 
reactive oxygen species. JP4 protective qualities mitigate radiation damage in blood cells in vitro 
and vivo.132-133 JRS is another analog of XJB however containing two nitroxide groups (Figure 
4.2) As the nitroxide group is the portion of the molecule responsible for scavenging ROS is 
expected this will increase potency. 
Similar to anti-inflammatory drugs, probes perfused with JP4 and JRS decreased but did 
not abolish evoked DA release near probes (Figure 4.5). JP4 and JRS all substantially increased 
the post-nomifensine response. For statistical analysis, maximum DA release was again 
normalized with respect to the maximum amplitude of the responses recorded pre- probe 
implanted. Histograms representing ROS effect on evoked DA release are represented in Figure 
4.6. A one-sample t-test was performed comparing XJB, JP4, JRS to zero (aCSF response post-
probe implantation). XJB and JRS significantly increased evoked DA release near probes (Figure 
4.6a). All responses post-probe with JP4 gave a measurable DA signal however, this increase 
was not significantly greater than zero. JRS significantly increased evoked DA release compared 
to aCSF (Figure 4.6b:  One-way AVONA comparing post-nomifensine responses with ROS 
scavengers and aCSF). Nomifensine increase all ROS DA responses, but it is clear that JRS had 
the greatest effect on protective evoked DA near probes, which was expected. 
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Figure 4.5. Average (±SEM) DA responses to a 25 s stimulation of recorded in the striatum pre-microdialysis probe 
implantation (blue), post-probe implantation (red), and post-probe, post-nomifensine (green). Microdialysis probes 
were perfused with either XJB, JP4, or JRS (n=6 rats per agent). Solid lines represent the mean response and dotted 
lines the SEM. Black diamond indicate the beginning and end of stimulation. XJB data previously published.32 
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Figure 4.6. Effects ROS scavengers retrodialysis of maximum evoked DA (a) post-probe implantation and (b) post-
nomifensine. (a) As DA was non-detectable in the case of aCSF a one-sample t-tests was performed to compare each 
post-probe response to zero. XJB, and JRS significantly increased maximum evoked DA compared to aCSF: One-
sample, one-tailed t-test XJB t(5)=2.02, *p<0.05, JRS t(5)=2.24, *p<0.05. (b) Post-nomifensine, JRS increased 
evoked DA compared to aCSF:  One-way ANOVA F(3,20)=3.98, p<0.05, post-hoc tukey test: JRS:  *p<0.05. 
4.3.5 Nomifensine Perfusion does not Impact DA Terminals 70-100 µm Away 
In a final study, nomifensine was administrated by perfusion through microdialysis probes 
instead of an i.p. injection. Voltammetry near probes perfused with nomifensine was performed 
in two groups of rats (n=3 rats/group), one group with perfusion of aCSF plus 1 µM 
nomifensine, and the other with perfusion of DEX plus 1 µM nomifensine. 
Post-probe implantation responses were recorded before nomifensine was added to the 
perfusion fluid and gave similar results to experiments performed previously.32 At probes 
perfused with only aCSF DA was not detected (Figure 4.7a) and at probes perfused with DEX, 
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evoked DA was measured (Figure 4.7b). Note that the aCSF results are reported as current 
(Figure 4.7a and 4.7c) as DA was undetected (aka. results did not produce a corresponding DA 
cyclic voltammograms). Nomifensine was added to each perfusion fluid and evoked DA 
responses were monitored near probes every 20 minutes for at least 2 hours. Nomifensine had no 
effect on evoked DA responses near probes whether DEX was present or not in the perfusion 
fluid. 
Nomifensine, a competitive DA transporter inhibitor was unable to act on DA terminals 
70-100 µm away from the probe. However nomifensine perfusion through microdialysis is 
known to increase extracellular levels of DA within 10 minutes of administration. When 
measured by microdialysis probes.107 Nomifensine is a smaller molecule than DEX; therefore it 
would expect to diffuse through brain tissue more efficiently than DEX. We have previously 
shown that DEX’s effects on evoked responses are attributable to its anti-inflammatory actions, 
not direct actions on DA terminals.33  This evidence further supports our conclusion that DEX is 
acting on the tissue and blood vessels to improve tissue health during inflammation as opposed 
to DEX acting on DA terminals specifically the DA transporter. 
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Figure 4.7. Effects of nomifensine added to perfusion fluid of microdialysis probes on evoked DA release near 
probes (n=3 rats/group). (a) Average (±SEM) current responses to a 25 s stimulation of the recorded in the striatum 
post-probe implantation with aCSF (red), and post-probe with aCSF plus nomifensine (green). (b) Average (±SEM) 
DA responses to a 25 s stimulation of the MFB recorded in the striatum post-probe implantation with DEX (red), 
and post-probe with DEX plus nomifensine (green). (c) There was no difference in maximum current post-probe 
implantation with aCSF (red), and post-probe with aCSF plus nomifensine (green), paired t-test (p>0.05). (d) There 
was no difference in maximum DA release post-probe implantation with DEX (red), and post-probe with DEX plus 
nomifensine (green), paired t-test (p>0.05). 
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4.4 CONCLUSIONS 
Our lab has previously shown that microdialysis probe implantation decreased evoked DA 
release in tissue near probes.29, 31-33 Through mitigation of the injury site with an anti-
inflammatory steroid, DEX, and a novel ROS scavenger, XJB, DA activity is preserved.32 Here 
we show other non-steroidal anti-inflammatory agents and ROS scavengers that protect DA 
release and uptake near microdialysis probes. IBU, PPads, XJB and JRS significantly attenuate 
the loss of DA activity in tissue near microdialysis probes. As we have previously shown long-
term protection with DEX preserves evoked DA release measured in tissue near the probe and at 
the outlet of probes, these drugs present other options to improve chronic microdialysis.33 
The protective effects were only partial, not completely restoring evoked DA release to 
its pre-probe response amplitude. Future dose response experiments are necessary to determine 
the optimal concentration of these agents and potential to completely restore DA activity near 
probes. Cocktails of these pharmacologically agents may also further promote evoked DA 
release in probe induced tissue damage. Overall, pharmacological enhanced microdialysis 
provides new insight into acute mitigation of microdialysis probe penetration injury and has the 
potential to successfully mitigate chronic implantation for long-term in vivo monitoring of 
neurochemicals. 
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5.0  THE EFFECT OF MICRODIALYSIS PROBE IMPLANTATION ON 
EXTRACELLULAR POTASSIUM IN SURROUNDING TISSUE 
I would like to acknowledge undergraduate researchers Kendra J. Bobby and Michael Rerick for 
their contribution to the data set presented in this chapter. 
5.1 INTRODUCTION 
In the United States 1.7 million people per year sustain traumatic brain injury (TBI) which 
results in 53,000 deaths.134 Days after a TBI event, forty percent of patients deteriorate due to the 
onset of a secondary injury.135 These secondary injuries occur in the hours and days following 
the primary injury and play a large role in the brain damage and death that result from TBI. The 
incidence of secondary injury is not restricted to brain trauma, but also occurs in other acute 
brain injuries such as intracranial hemorrhage, ischemic stroke.136-137 
Secondary injuries are suspected to be caused by spreading depolarizations (SDs). Recent 
studies confirmed that the incidence of SDs was a significant risk factor that predicted outcomes 
in patients with head trauma.138 Based on the incidence of SD during days after initial treatments 
in the intensive care unit, it has now been suggested that SD is an important target to prevent 
progression of injury.139-140 SDs are propagating waves of near complete depolarization of a 
volume of tissue, including both neurons and glial cells. SDs are generally initiated by a harsh 
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stimulation (e.g. potassium, ischemia) that severely depolarizes local brain tissue. This initiating 
depolarization results in a loss of transmembrane ionic gradients, significant cellular swelling, 
continuous potassium efflux and release of neurotransmitters including glutamate.141 It is the 
accumulation and diffusion of these excitatory solutes which trigger severe depolarization of 
neurons and glia in the surrounding tissue, that slowly spreads across brain tissue at a rate of 2-5 
mm/min.141 The large ion fluxes associated with SD result in modulation of extracellular ionic 
concentrations and cause large shifts in extracellular field potential.142 The wave-front of SD is 
thus electrically detected as a steep extracellular DC potential shift.  This sharp potential shift 
coincides with a steep drop in the extracellular sodium concentration and increase in 
extracellular potassium concentration. It is widely assumed that SDs generated in metabolically 
compromised tissue sets up an additional metabolic burden that contributes to neuronal damage. 
Currently, SDs and their metabolic products are studied in traumatic brain injured 
patients using online rapid sampling microdialysis.9, 34, 36, 143 This method can detect metabolic 
signatures of SD with 1 minute temporal resolution. Temporal profiles of SDs can be achieved 
using rapid sampling microdialysis in combination with online potassium ion selective electrode 
(ISE) to detect potassium changes and hence the start of an SD event. 
A serious limitation with this approach is that microdialysis probe implantation causes a 
penetration injury that triggers ischemia and gliosis at the sampling site due to the large size of 
the microdialysis probe (200-300µm).14-16, 18, 26, 32, 93 The wounded tissue at the sampling site is 
different from the surrounding parenchyma:18 ischemia impacts delivery of metabolic substrates 
to the probe and gliosis slowly develops, so the sampling site evolves over several days 
following insertion.26 Microdialysis probes disrupt neurotransmission in the brain, specifically 
probe implantation decreases the release of the neurotransmitter dopamine.29, 31-33, 108 It is 
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possible that probes also affect potassium concentrations in the brain which would in turn 
compromise the detection of SDs. In a study monitoring potassium concentration changes during 
an ischemia event, ISE (size:  <50 µm) monitoring directly in the brain tissue measured much 
greater changes in potassium concentrations than microdialysis probes coupled online to an 
ISE.144 
Potassium is a key marker for monitored SDs in TBI patents therefore it is important to 
understand if and how penetration injury affects potassium levels in the brain. Thus, it is the goal 
of this study to investigate whether probes significantly impact the monitoring of brain 
potassium levels during SDs to determine the reliability of clinical microdialysis. 
Previously our lab has investigated the impact of microdialysis probes on evoked 
dopamine release in tissue near the probe. Decreasing the proximity from the probe creates a 
gradient decrease in evoked dopamine release.29  Probes impact dopamine release in tissue 
adjacent to the probe,29 100 µm,32 200 µm from the probe, but have no effect 1 mm away.29 
Following this lead, we used potassium ion selective microelectrodes (ISME) to monitor 
potassium in the cortex of the rat brain. We implanted microdialysis probes in tissue 1 mm from 
ISME to determine the effect of probe implantation on potassium levels and its effect on the 
measurement of SDs. 
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5.2 EXPERIMENTAL SECTION 
5.2.1 Reagents and Solutions 
All solutions were prepared with ultrapure water (NANOPURE; Barnstead, Dubuque, IA). All 
reagents were used as received. Artificial cerebrospinal fluid (aCSF: 142 mM NaCl, 1.2 mM 
CaCl2, 2.7 mM KCl, 1.0 mM MgCl2, 2.0 mM NaH2PO4, pH 7.4) was used as the perfusion fluid 
for microdialysis. All potassium solutions were made by dissolving KCl (Sigma Aldrich, St. 
Louis, MO) in artificial cerebrospinal fluid without potassium (aCSF without K+: 142 mM NaCl, 
1.2 mM CaCl2, 1.0 mM MgCl2, 2.0 mM NaH2PO4, pH 7.4). The silanizing agent used was 
hexamethyldisilazane (Sigma Aldrich, St. Louis, MO). Valinomycin was used as the potassium 
ionophore and purchased in a cocktail solution (Potassium Ionophore 1-cocktail, Sigma Aldrich, 
St. Louis, MO). 
5.2.2 Potassium Ion Selective Microelectrodes (ISME) and Microdialysis Probes 
Potassium ISME were constructed using borosilicate capillaries (0.58 mm I.D., 1.0 mm O.D., 
Sutter Instruments, Novato, CA). Capillaries were cleaned by soaking in acetone for 30 minutes 
and dried vertically at 70 °C for 2 hours. Capillaries were pulled to fine tips with a vertical puller 
(Narishing Tokyo, Japan) and gently broken to open the tip. The tip size of the electrodes were 
<50 µm. The electrodes were silanized by backfilling the capillary tips with 
hexamethyldisilazane. Silanization took place for 2 hours, then electrodes were placed tip down 
in the oven to dry for 2 hours at 200 °C (protocol provided by D. Feuerstein). 
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Electrodes were built by first dipping the tip of the electrode into potassium ionophore 1-
cocktail.145 The remainder of the electrodes were backfilled with 10 mM KCl.  Ag/AgCl wire 
was inserted into the KCl solution completing the electrical contact (Figure 5.1). The end of the 
electrodes was sealed using 5-min epoxy (Devcon, Davers, MA). 
Microdialysis probes were constructed in-house as previously described.32 
Figure 5.1. Potassium ISMEs consist of a capillary pulled to a fine tip. The tip contains a valinomycin cocktail. The 
electrode is backfilled with a 10 mM KCl. Electrical contact is made by a Ag/AgCl wire. 
5.2.3 Potassium Detection 
The potential verse a Ag/AgCl reference electrode was monitored by a differential amplifier 
(DP-301:  Warner Instruments LLC, Hamden, CT) and recorded using a digital converter (NI-
USB-6009 National Instruments, Austin, TX) linked to a Labview computer software program 
(Chuck Fleishaker, electronic shop, University of Pittsburgh). 
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Potassium concentrations were determined by pre-calibration of electrodes with at least 
five different concentrations of KCl dissolved in aCSF without K+. Normal calibration curves 
had slopes of 50-58 mV for a 10 fold change in potassium. 
5.2.4 Animals and Surgical Procedures 
All procedures involving animals were performed under approval of the Institutional Animal 
Care and Use of Committee of the University of Pittsburgh. Adult male Sprague-Dawley rats 
(250-350 g; Charles Rivers, Raleigh, NC) were anesthetized with isofurane (2.5 % by volume, 
Baxter Healthcare, Deerfield, Il), intubated and placed in a stereotaxic frame. Anesthesia was 
maintained throughout the rest of the experiment. The skull was exposed and holes were drilled 
into the skull to access the brain. 
Potassium ISME were implanted at a 5 degree angle in the cortex of the rat brain (1.0 mm 
anterior from bregma, 2.85 mm lateral from bregma, and 1.0 mm below dura). Electrical 
connection between the brain and a Ag/AgCl reference electrode was achieved by creating a salt 
bridge with a Kimwipe soaked in aCSF placed in a plastic pipette tip. Potassium was 
continuously measured throughout the whole experiment. Once a stable baseline was reached, an 
18 gauge needle was used to prick the surface of the rat brain. After three needle pricks, a 
microdialysis probe was implanted into the cortex 1 mm from the ISME. With the probe in place, 
three more needle pricks were performed in the same location as pricks performed before the 
probe was implanted. Potassium levels were allowed to return to a stable baseline between 
needle pricks and after probe implantation. 
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5.3 RESULTS AND DISCUSSION 
ISME were used to continuously monitor potassium levels during induced SD events. SD events 
were brought on by a needle prick to the surface of the brain. A typical experiment consisted of 
three needle pricks (NP), implantation of a microdialysis (MD) probe, then three more needle 
pricks (Figure 5.2). All experiments were performed in a Faraday cage, reducing outside 
interference with the ISME. Entering the cage to perform the needle pricks created a non-
potassium related potential spike in the data; however we determined that this interference did 
not affect the monitoring of SDs as the wave did not reach the ISME for a least 1 minute after 
each needle prick. Extracellular basal potassium concentration was between 2-3 mM throughout 
the experiment which is consistent with the potassium concentration in rat cerebral spinal fluid 
(2.7 mM). Needle pricks caused a large increase in extracellular potassium as measured by 
ISMEs. 
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Figure 5.2. Representative experiment illustrating potassium concentration in the rat cortex vs. time. In the top 
portion of the graph, a potassium ISME was implanted at t=0 min. Needle pricks (NP) were performed followed by 
an observed increase in potassium concentration. In the bottom portion of the graph, a microdialysis (MD) probe 
was implanted at t=66 min followed by a large increase in potassium needle pricks trailing probe implantation were 
measure by ISME. Large spikes in the data are non-potassium related noise. 
Potassium responses to needle pricks before microdialysis probe implantation were 
averaged ±SEM (Figure 5.3, n=7 rats). Basal potassium concentration before the needle prick 
was set to zero and the time of the prick was also set to zero. Needle pricks before probe 
implantation caused a 2.78 ± 1.37 mM change in potassium concentration in the cortex. The SD 
itself lasted for approximately two minutes. 
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Figure 5.3. The change in potassium in response to needle pricks performed before microdialysis probes were 
implanted (n=7 rats). Data was adjusted so that needle pricks were at t=0 min. The spike just before t= 0 is noise 
caused by opening of the Faraday cage to perform the needle pricks; it is not a change in potassium. The solid purple 
line represents the average response, and dotted lines represent ±SEM for this figure and all remaining figures. 
Microdialysis probes were implanted 1 mm away from ISME (Figure 5.4, n=7 rats). In 
five out of seven animals, probe implantation caused a SD, confirmed by a drastic increase in 
potassium concentration directly after probe implantation. The response to probe implantation 
was greater (4.06 ± 2.80 mM) than the SD’s created by needle pricks. This may be due to the 
outer diameter of the probe being greater than that of the needle. In the animals in which a SD 
was not seen due to probe implantation, it was confirmed that the electrodes were still 
functioning. It is most likely that the SD event “missed” the ISME as SD waves do not follow a 
specific pattern.143 
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Initially, it was concerning that microdialysis probe implantation elicits an SD wave. 
Only one SD event was observed per probe implantation, implying that the probe induced injury 
was not severe enough to encourage multiple SD (as occurs in TBI).34 Occasionally, 
implantation of the much smaller ISME would cause a small SD (Figure 5.1, t=0). The 
potassium levels return to baseline within a similar time frame as the potassium levels during a 
pre-probe needle pricks (2-3 minutes). It does not appear that probe implantation causes 
continuous SD’s and thereby secondary injury to nearby tissue. 
Figure 5.4. The change in potassium in response to microdialysis probe implantation (n=7 rats). Probes were 
implanted in all seven rats, however in 2 out of the 7 rats, a potassium change was undetected at the ISME.  Data 
was adjusted so that microdialysis probes were implanted at t=0 min. The spike in the data just before t=0 min, is 
attributed to opening the Faraday cage to lower the probe: it is not a change in potassium. 
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After microdialysis probes were implanted and the potassium concentration returned to 
baseline, needle pricks recommenced. Changes in potassium were always observed following 
probe implantation in tissue 1 mm away (Figure 5.5). Average potassium changes to needle 
pricks post-probe (3.21 ± 2.30 mM) were similar compared to pre-probe responses. It appears as 
though the SD event is delayed post-probe implantation but we cannot confirm this, as the needle 
prick location was not consistently measured. Location of the needle prick alters the time in 
which it takes the SD wave to travel to the ISME. Overall, microdialysis probe implantation did 
not impact measurements SD events in tissue 1 mm away. Microdialysis probes do not affect the 
amplitude of potassium increase induced by a needle prick. 
Figure 5.5. The change in potassium in response to needle pricks (NP) performed after microdialysis probes were 
implanted (n=7 rats). Data was adjusted so that needle pricks were at t=0 min. The spike just before t=0 is noise 
caused by the opening of the Faraday cage to perform the needle prick: it is not a change in potassium. Microdialysis 
probes did not affect the detection of potassium changes in the cortex. 
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5.4 CONCLUSIONS 
Clinical microdialysis is currently used to monitor SD events in traumatic brain injured patients. 
As microdialysis probe implantation disrupts surrounding tissue, it is imperative to determine 
probe implantation’s effect on monitoring SD events. Here, we demonstrated that microdialysis 
probe implantation does not affect potassium changes during an SD event measured 1 mm away. 
Microdialysis probe implantation causes a SD, however it does not impact the overall monitoring 
of succeeding SDs. This data represents a preliminary study to determine effects of probe 
implantation on potassium levels in surrounding tissue. As microdialysis samples from tissue 
directly next to the probe, further experiments involving electrode placement closer to the 
microdialysis probe are required to determine if potassium levels in adjacent tissue are affected. 
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6.0  SPATIAL MAPPING REVEALS FUNCTIONAL DOPAMINE SUB-REGIONS OF 
THE STRIATUM THAT CORRESPOND TO PATCH-MATRIX COMPARTMENTS 
Partial contents of this chapter were previously published in:  Taylor, I.M., Nesbitt, K.M., 
Walters, S.H., Varner, E.L., Shu, Z., Bartlow, K.M., Jaquins-Gerstl, A.S., Michael, A.C. J. 
Neurochem. 2015, doi: 10.1111/jnc.13059. 
I would like to acknowledge that the immunohistochemistry work in this chapter was performed 
by Andrea Jaquins-Gerstl. 
6.1 INTRODUCTION 
Dopamine (DA) is an immensely important neurotransmitter in the central nervous system.  It 
contributes to motor control, reward-based learning, the regulation of mood and anxiety, and 
several other brain functions.146-147  Pathology of the central DA systems is clearly implicated in 
Parkinson’s disease, dystonia, schizophrenia, attention deficit hyperactivity disorder, and 
substance abuse.148-151  Consequently, drugs that target DA systems have wide-ranging 
therapeutic applications and illicit uses.  So, understanding brain DA activity per se and the 
mechanisms of action of DA-targeting drugs is immensely significant.35, 152  Our previous 
findings, derived from voltammetric recordings in the rat brain, show that the dorsal striatum is 
organized as a patchwork of distinct DA kinetic domains.53, 106, 153-154  We have named these 
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kinetic domains fast and slow because the initial rates of DA release are significantly faster in the 
former compared to the latter domains. These domains also respond differently to 
pharmacological manipulations with DA receptor antagonists and DA transporter inhibitors.53, 
106, 155  Our objective in this study is to explore their anatomy: we wish to know the distribution 
of the domains, and their anatomical relationship to the neurochemical marker of striatal 
structure, the µ-opiate receptor.  The striatum is composed of a mosaic of spatial compartments 
known as the striosomes (patches) and the matrix. Extensive literature exists on the spatial 
organization of the patch and matrix compartments and their functions. However, little is known 
about these compartments as they relate to fast and slow kinetic DA domains observed by fast 
scan cyclic voltammetry. We achieve this objective by combining high spatial resolution 
voltammetric mapping with detailed immunohistochemical analysis these architectural 
compartments (patch and matrix) by means of fluorescence microscopy. 
The discovery of these domains was an innovation in its own right, shedding new light on 
DA’s spatial and kinetic heterogeneity.  In this study, we used fast scan cyclic voltammetry 
(FSCV) to systematically characterize the domains as they pertain to two distinctive DA terminal 
fields the dorsal medial striatum (MS) and dorsal lateral striatum (LS) which has not been 
attempted before as far we know.  The FSCV literature contains no examples of comprehensive 
striatal mapping such as we have done. Also, we correlate the domains with the known 
architecture of the striatum as embodied in the patch and matrix compartments (this subject is 
widely known and has been thoroughly reviewed.156-157  Our work provides much more detail 
and much higher spatial resolution by using carbon fiber microelectrodes and FSCV.  Detailed 
correlations between FSCV recordings and histochemical tissue markers, while not unheard 
of,158-159 are quite rare and we are the first to correlate FSCV with patch and matrix 
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compartments via immunohistochemistry using the µ-opiate receptor. Our findings demonstrated 
a direct correlation between patch compartments with fast domain DA kinetics and matrix 
compartments to slow domain DA kinetics. We also investigated the kinetic domains in two very 
distinct sub-regions in the striatum. The lateral striatum as opposed to the medial striatum is 
mainly governed by fast kinetic DA domains. These finding are highly relevant as they may hold 
key promise in unraveling the fast and slow kinetic DA domains and their physiological 
significance. 
6.2 EXPERIMENTAL SECTION 
6.2.1 Carbon Fiber Microelectrodes 
Borosilicate capillaries (0.58 mm I.D., 1.0 mm O.D., Sutter Instruments, Novato, CA), each 
containing a single carbon fiber (7µm diameter,T650, Cytec Carbon Fibers LLC., Piedmont, 
SC), are pulled to a fine tip using a vertical puller (Narishige, Los Angeles, CA, USA) and the tip 
is sealed with epoxy (Spurr Epoxy, Polysciences Inc., Warrington, PA, USA).  Carbon fibers 
were cut to a length of 200 μm from the base of the capillary. The capillaries were filled with 
mercury and a nichrome wire (Goodfellow, Oakdale, PA) was inserted to complete electrical 
contact. Microelectrodes were pre-treated by soaking the tip in isopropyl alcohol (Sigma Aldrich, 
St. Louis, MO) for one hour. 
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6.2.2 Fast-Scan Cyclic Voltammetry 
Voltammetry is performed with the EI 400 (Ensman Instruments, Bloomington, IN) and CV Tar 
Heels v4.3 software (Dr. Michael Heien, University of Arizona, Tucson AZ).  The reference 
electrode is Ag/AgCl.  The waveform starts at 0 V vs. Ag/AgCl, ramps linearly (400 V/s) to +1.0 
V, then to -0.5 V, and returns to 0 V.  The scan frequency is 10 Hz (scans at 100 ms intervals).  
DA is identified by the background-subtracted voltammograms and quantified from the 
magnitude of the oxidation current between 0.5 and 0.7 V. Calibration is performed in a flow cell 
with N2-spurged artificial cerebrospinal fluid (aCSF:  142 mM NaCl, 1.2 mM CaCl2, 2.7 mM 
KCl, 1.0 mM MgCl2, 2.0 mM NaH2PO4, pH 7.40) containing freshly prepared DA (dopamine 
HCl, Sigma Aldrich, St. Louis, MO, USA) standards. 
6.2.3 In vivo Procedures 
All in vivo animal procedures were performed under approval of the Institutional Animal Care 
and Use of Committee of the University of Pittsburgh.  Male Sprague-Dawley rats (250-350 g 
Charles Rivers, Raleigh, NC) are intubated and anesthetized with isoflurane (2.5% by volume) 
placed in a stereotaxic frame and wrapped in a 37˚C heating pad (Harvard Apparatus, Holliston, 
MA, USA).  Holes are drilled through the skull for the reference, stimulating, and working 
electrodes. Two carbon fiber electrodes were implanted into the striatum (coordinates below). A 
stimulating electrode (bipolar stainless steel, MS303-1-untwisted, Plastics One, Roanoke, VA) 
was positioned over the medial forebrain bundle (MFB-4.3 mm posterior to bregma, 1.2 mm 
lateral from bregma, and 7.2-8.5 mm below the dura). The stimulating electrode was lowered 
until evoked DA was measured at both carbon fiber electrodes in the striatum. The electrical 
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stimulus is optically isolated and a biphasic, constant-current, square wave with the following 
parameters: 2 ms per pulse, 250 μA pulse height, and 60 Hz pulse frequency, 0.2, 1, or 3s 
duration (Neurolog 800, Digitimer, Herefordshire, England).All experiments were completed in 
the right hemisphere. 
6.2.4 Classification of Fast and Slow Domains 
In our previous studies,53, 106, 153-154, 160 we identified fast and slow domains by means of a brief 
stimulus test (60 Hz, 250 μA, 200 ms). Recording sites that respond to the test stimulus are 
classified as fast: otherwise, they are classified as slow. Fast sites respond immediately to the 
stimulus and slow sites exhibit an initial lag. Most of the responses reported were evoked with 
the experimental stimulus selected for this work (60 Hz, 250 μA, 3 s). 
6.2.5 Striatal Mapping 
We implanted n=20 carbon fiber electrodes in the striatum of n=10 individual rats (two new 
electrodes per rat). One of these was implanted in the MS (1.6 mm anterior to bregma, 1.5 mm 
lateral from bregma, and 4.5 mm below the cortical surface) and the other in the LS (0.2 mm 
anterior to bregma, 3.8 mm lateral from bregma, and 4.5 mm below the cortical surface).161 The 
two electrodes were stereotaxically lowered in 5x200 μm intervals (total track length = 1.0 mm). 
Each recording site was evaluated with the test stimulus (60 Hz, 250 μA, 200 ms) and the 
experimental stimulus (60 Hz, 250 μA, 3 s). After the recording session, the electrodes were 
lowered an additional 500 μm and used to mark the bottom of the track with an electrolytic 
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lesion (35-V AC 10 s). Post-mortem histological analysis confirmed that all the electrodes were 
properly positioned, consistent with their intended stereotaxic target. 
6.2.6 Data Analysis 
Statistical analysis of Figure 6.6 was performed by 3-way ANOVA with time (repeated 
measure), track, and depth as factors: time. Statistical analysis was performed with IBM SPSS 
software version 22. 
6.2.7 Tissue Fixation and Processing 
Tissue fixation, processing, immunochemistry and fluorescence microscopy followed our 
published procedures.17-18 After in vivo recording, rats were perfused with PBS, 
paraformaldehyde, and a suspension of fluorescent beads (0.1 μm diameter, Molecular Probes: 
the beads label blood vessels and provide an assessment of vascular damage, which is minimal 
with these microelectrodes).  The tissue was submerged in 2% paraformaldehyde for 2 hours and 
30% sucrose overnight, frozen in liquid nitrogen-cooled 2-methylbutane, and stored at -80°C 
until sliced horizontally in a cryostat into 30-μm thick sections.  The sections were placed into 
24-well plates with cryoprotection solution and stored at 20°C until immunolabeling was 
performed. 
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6.2.8 Immunofluorescence Protocol and Fluorescence Microscopy 
Tissue sections were labeled with antibodies (markers discussed below) and DAPI to visualize 
nuclei. Sections were examined by fluorescence microscopy (Olympus BX61, Olympus; 
Melville, NY) with a 1.25X or 10X objective and wavelength matched filter sets (Chroma 
Technology; Rockingham, VT).  Images were analyzed and quantified with Metamorph/Fluor 
7.1 (Universal Imaging Corporation; Molecular Devices), NIS Elements AR (Nikon Corporation; 
Tokyo, Japan) and OriginPro. 
Using immunohistochemistry with tyramide signal amplification (TSA) protocol on free- 
floating sections we determined distributional patterns of the µ opioid receptor, MOR,  (Koizumi 
et al 2013, Okita et al 2012). Rabbit polyclonal MOR antibodies (1:100,000; Millipore), was 
used as the primary antibody. Tissue sections were left in the primary antibody in a 20% goat 
serum blocking solution at room temperature for 48 hours. The bound primary antibody was 
detected with fluorescein (Perkin Elmer, Shelton, CT). 
6.3 RESULTS AND DISCUSSION 
6.3.1 Defining the Lateral and Medial Striatum 
An extensive body of literature describes the anatomical studies which delineates the striatal sub-
regions in terms of their afferent and efferent cortical projections.156-157 The dorsal striatum in 
rodents is not clearly divided into caudate and putamen, however it does have a medial-lateral 
gradient of connectivity which is similar to the caudate and putamen connectivity of primates.162-
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163  The medial portion of the dorsal striatum extends ventrally to the limits of the accumbens; it 
has been demonstrated to receive most of its input from associative areas of the cortex (i.e. 
caudate), whereas, the dorsal lateral striatal region receives input from the sensorimotor areas of 
the cortex like the putamen.163 Furthermore, a gradient of behavior functions spans laterally 
across the striatum.164-166  In our studies we have examined the distinct DA kinetics differences 
between the MS and the LS. 
6.3.2 Domain Classification with Microelectrodes 
To date, we have used microelectrodes to study DA’s domains; the use of such small devices 
takes advantage of their higher spatial resolution. (Figure. 6.1). Figure 6.1 reports stimulus 
responses from six consecutively deeper recordings sites along a single microelectrode track 
(dorsal to ventral) in the LS track.  Recording sites that do not respond to 200-ms stimuli are 
classified as slow (middle and right panel): these sites do respond to longer stimuli.  Recording 
sites that do respond to 200 ms stimuli (left panel) are classified as fast.  The far right panel 
indicates individual classification associated with the individual recording site described above. 
Three different stimulus lengths were recorded for each site 200 ms, 1 s and 3 s (60 Hz, 250 µA).  
The fast and slow responses are clearly distinct, so the classification is objective. Thus, Figure 
6.2 confirms that it is feasible to both classify and map domains with microelectrodes in the 
same individual animal. In this particular example, Figure 6.2, most of the responses are 
predominately fast except for one (4.5mm below dura). 
Using two carbon fiber electrodes simultaneously we were able to observe, for the first 
time, fast and slow DA responses during a single stimulation of the MFB (Figure 6.2). During a 
200 ms stimulation of the MFB, evoked DA was measured at one electrode (left-red) and not 
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detected at the other electrode (left-blue).  However, a longer stimulation (3s) produced evoked 
DA responses measurable at both electrodes. This confirms that the position of the stimulating 
electrode in the MFB doesn’t cause DA responses to be fast or slow in the striatum. Diversity of 
DA responses is based on electrode location in the striatum. 
Figure 6.1. A representative set of individual responses recorded along a the LS track in a single animal. Three 
different test stimuli were recorded 200 ms, 1 s and 3 at 60 Hz, 250 µA. Each evoked response was then classified as 
either fast or slow (far right column). 
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Figure 6.2. Individual representations of evoked DA responses during stimulation of the MFB measured by two 
electrodes implanted in different electrodes in the striatum. 
6.3.3 Evoked DA Responses in the Medial and Lateral Striatum 
It is well known that the kinetics of evoked DA release in the striatum is heterogeneous.167-169 
Although the practice of voltammetry often seeks “hot spots,” sites that produce maximally 
concentrations of DA, this has created the impression that the striatum contains two types of DA 
responses “hot spots” and “cold spots,” sites that produce less concentrations of DA.159, 170-172 
This idea undermines the ultrastructure of the striatum; studies show that the striatum contains 
DA terminals regularly spaced at 2-5 μm intervals.173 Complex arrays of DA terminal are 
arranged in a lattice like structure, meaning that recording electrodes in the striatum are always 
physically close to DA terminals. Presently, the literature contains no explanation for what 
constitutes “hot” and “cold” spots or if there is functionality differences between the two.  
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We have investigated evoked DA responses and further classified them based on their 
kinetic responses to stimulation (fast and slow). A recent publication from our group shows that 
in the dorsal striatum, functionally distinct sub-regions express DA kinetic diversity in five 
different response types (1 slow and 4 fast) in the same location of the striatum of n= 168 
individual animals.154 Here, we have demonstrated that very distinctive kinetic differences are 
prominent even in the same electrode track of the same animal (Figure 6.3). Under the same 
stimulus conditions, 3s, 60 Hz stimulation, there is direct evidence of DA’s heterogeneity in the 
striatum. The color coded arrows in the middle panel correspond to the individual FSCV 
recording and their classification (fast or slow). What is obvious is that the kinetic behaviors 
change frequently from slow-fast-slow (left hand electrode track) and vice versa, differences are 
within 0.2 mm (dorsal to ventral) separation. 
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Figure 6.3. Individual evoked DA responses from two different electrode tracks of the same animal. Kinetically 
different DA responses change as the electrode is moved from dorsal to ventral in the striatum. Blue represents slow 
domains and red fast domains. The center arrows correspond to each electrode track; they are color coded to match 
the individual recording locations. 
6.3.4 Fast Domains Prevail in the Lateral Striatum 
Prior studies have identified fast and slow kinetic domains in the DS,53, 106, 153-155, 160 and also in 
the core of the nucleus accumbens.174-175  Further investigations into the striatum in this study 
now reveal that evoked DA responses recorded from the MS and the LS have very distinct 
kinetic profiles (Figure 6.4). Using n=20 individual electrodes to record evoked DA release at six 
sites along the MS and LS (n=10 rats). The right panels of Figure 6.4 give the location of each 
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recording site and count the number of times each site was classified objectively as fast (by 
means of a response to a 200 ms stimulation). The left panels of Figure 6.4 report averages of the 
responses at each site (SEMs reported in Figure 6.5).  Responses recorded along the MS track 
and the LS, located in the medial and lateral sub-regions of the striatum, respectively, are distinct 
in both amplitude and profile. The responses along the MS track are predominantly slow while 
those along LS track are predominantly fast.  The difference in response amplitudes between, but 
not within, the MS and LS tracks is statistically significant (Figure 6.6). These findings strongly 
support the conclusion that DA’s kinetic diversity is sub-region dependent and that fast domains 
are more readily found in the LS than the MS. 
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Figure 6.4. Striatal mapping along the MS track (top) and the LS track (bottom). Right Panels: the boxes show the 
anatomical location of each recording site and the number of fast responses observed at each location red represents 
fast and blue represents slow). Left Panels: average of the responses long the MS and the LS (n=10 electrodes per 
track, 1 track each per rat; SEMS reported in Figure 6.5). 
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Figure 6.5. The averaged responses from Figure 6.4 (solid lines; n=10 electrodes per track, two tracks per animal) 
shown separately with their SEMs (dashed grey lines). See Figure 6.6 for statistical analysis. 
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Figure 6.6. Evoked DA concentrations (mean ± SEM, n=10 electrodes per track, 2 tracks per rat) at t=0.2 , 1 , and 3 
s after the onset of the stimulus. Statistical analysis was by 3-way ANOVA with time (repeated measure), track, and 
depth as factors: time F(2, 216)=153.7, p< 0.00001); track F(1, 108)=51.0, p<0.00001; time * track interaction 
F(2,216)=64.4, p<0.00001; depth was not a significant factor. Bonferroni post-hoc pairwise comparisons: the 
difference in amplitudes between Track A and Track B are significantly different at t=1 s (*p< 0.00001) and at t=3 s 
(Ϯp<0.00001): differences in amplitudes within each track are not significant. 
6.3.5 Correlation to Patches-Matrix Compartments 
The anatomical organization of the striatum includes the patch: matrix compartmentalization and 
the direct and indirect pathways (for a detailed review, see (Crittenden & Graybiel 2011)).156 The 
patches and matrix receive distinct DA inputs from the substantia nigra pars compacta (SNc), 
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while striatal neurons from the patches, but not the matrix, selectively project to the SNc. This 
provides a basis for anticipating anatomical organization of the DA terminal field as well. 
Investigators have previously speculated that a relationship might exist between the 
heterogeneity of evoked DA release and the patch-matrix striatal compartments.169, 176 Moreover, 
the medial and lateral sub-regions of the DS are functionally distinct,164-166 so it is also relevant 
to ask if such sub-regions are distinct with respect to DA kinetic diversity. 
The μ opioid receptor and calbindin are widely used markers for the patch and matrix, 
respectively.158, 177 In our study we labeled for only the μ opioid receptor (patch), within the 
striatum, if the tissue is not label with the μ opioid receptor then the surrounding area is 
designated as the matrix compartment. We correlated the electrochemical recordings with this 
marker in the two separate electrode tracks MS and LS shown in Figure 6.7. 
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Figure 6.7. Scheme depicting the two electrode tracks and the patch-matrix compartments. Top represents the 
regions in the MS and bottom represents l regions in the MS. Blue and red patches correspond to slow and fast 
domains, respectively, that are in physical contact with the electrode. MS is 1.6 mm anterior to bregma, 1.5 mm 
lateral from bregma, and 4.5 mm below the cortical surface.  LS is 0.2 mm anterior to bregma, 3.8 mm lateral from 
bregma, and 4.5 mm below the cortical surface, coordinates of Paxinos and Watson161. 
6.3.6 Determination of the µ-Opiate Receptors Rich, Patches-Matrix Compartments 
We used polyclonal antibodies against C-terminal synthetic peptides for µ-opiate receptors, 
(MOR) in this study. Marked variations in the density and localization of the MOR were seen on 
horizontal sections of 30 µm sections of striatal tissue lesioned with a carbon fiber electrode, 
Figure 6.8. Electrolytic lesions made with the carbon fiber electrode were inconsistent; if lesions 
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were larger than three 30 µm sections, immunohistochemistry was not performed. If the lesion 
destroyed (burned) the tissue then immunohistochemistry was not performed. Only in 
experiments where lesions were contained within three 30 µm sections or less was staining 
performed for the MOR. Figure 6.8A is a differential interference contrast image of a horizontal 
tissue slices where a lesion made 500 µm below the last voltammetric recording; this is indicated 
in the darker area of the tissue in the LS (circled in red).  
Using this antibody single-labeled immunohistochemistry showed heightened 
immunoreactivity for MOR in striatal slices. No specific immunoreactivity was found in other 
sections of tissue (Figure 6.8B and 6.8C). Obvious MOR labeling exhibited a striking mosaic 
distribution in the striatum, highly concentrated labeling in the patches and subcallosal streak 
was present.178-179  A large matrix field (absence of labeling) is present in all striatal tissue slices. 
The subcallosal streak is in agreement with other studies using [3H] naloxone binding which 
borders the striatum; this was observed in all sections.180-181  In the rat [3H] naloxone binding is 
generally used for autoradiographic visualization of striatal patches.178-179  In figure 6.8B highly 
concentrated labeling in the patches and subcallosal streak are clearly evident, however, some of 
the myelinated axon bundles are visible but are less intensity compared to the patches. These 
myelinated axon bundles can be observed in Figure 6.8A as dark brown-black regions, for this 
reason, DIC images of each section were superimposed onto the fluorescence MOR labeled 
images to differentiate the patches from the myelinated axon bundles, see Supporting 
Information Figure S6.1. 
Patches with the lowest fluorescence intensity were determined and used as a threshold to 
draw the outline of individual patches on horizontal sections using NIS Elements AR software 
(Figure 6.8D).  An electrode drawing (drawn to scale) was superimposed on to these “outlined” 
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patches.  If the electrode was in physical contact with a patch, from these drawings, the patch 
was outline in the corresponding FSCV recording (blue: slow domain, red: fast domain). 
Figure 6.8. A representative collage of striatal patches identified by MOR immunohistochemistry staining. A) 
Differential interference contrast image of a horizontal tissue slices. The red circle indicates were the electrolytic 
lesion is on the tissue. B) This same section labeled for MOR (patches) in the bright green regions. The matrix is 
indicated by an absence of labeling (meaning no green regions). C) A black and white image of (B). D) Computer 
drawn patches based off a set threshold values of fluorescence intensities with an electrode drawing (drawn to scale) 
superimposed onto these patches. Color coded corresponding FSCV recording are presented on this schematic. Scale 
bars are 500 µm.  
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6.3.7 Mapping High-Resolution Voltammetric Recording of DA to Patch-Matrix 
Compartments 
The FSCV literature contains no examples of comprehensive striatal mapping. We have 
correlated the domains with the known architecture of the striatum as embodied in the patch and 
matrix compartments. Past attempts have been described this in a series of papers from the 
Glowinski group in the 1990s.181 Most of these studies used 3H-DA efflux from striosome-
enriched regions of the striatum to associate DA kinetics with the striosomes. Detailed 
correlations between FSCV recordings and striosomes (patches) and matrix are demonstrated in 
Figure 6.9. Patches were outlined in green as previously described. The electrode track in Figure 
6.9 is in the LS, as the electrode is lowered (dorsal to ventral) DA responses are collected. Each 
recording corresponds to the evoked DA profile to the right of the figure. All responses were 
classified as fast or slow domains. For clarity, we have color coded the electrode track and the 
evoked DA responses (red: fast domains and blue: slow domains.) If the actual electrode appears 
to physically touch a patch then the corresponding evoked DA response is outlined in a green 
box. 
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Figure 6.9. Represents mapping high-resolution voltammetric recording of DA in the striatum to MOR rich (patch) 
and poor (matrix) compartments. Drawing of the electrode track is superimposed onto tissue sections stained for 
MOR. FSCV recordings correspond to the electrode track (middle panel). If the electrode comes into contact with 
the patch then the voltammetry is outlined in a green box. Scale bar is 500 µm. 
6.3.8 Comparisons of the Patch-Matrix Compartments in the Medial Striatum and the 
Lateral Striatum 
A total of 7 different striatal tissue slices in the LS (n=2) and MS (n=5) were used to compare 
evoked DA responses (42 recordings) and MOR staining (Figure 6.10). The majority of the MS 
was made up of matrix. Of the 30 evoked DA responses recorded in the MS, the majority were in 
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the MOR poor (matrix) compartments, only a small number of patches (<17%) came into contact 
with the electrode track. In the MS only one of evoked responses was considered fast domains. 
Results for the LS were somewhat different than the MS; the evoked DA responses were 50% 
matrix and 50% patches. All of patches touching a recording site in the LS were also classified as 
fast domains. This came as somewhat of an unexpected finding but confirms our hypothesis that 
a relationship exists between the heterogeneity of evoked DA release and the patch-matrix 
striatal compartments. Because the domains are a feature of DA terminal fields in the striatum, 
we presume them to be physiologically significant although we have not yet identify how so 
exactly.  
In summarizing these findings in donut plots (Figure 6.11A) the amount of patches 
present in fast domains was 87.5% while only 12.5% of these were matrix. The opposite is true 
for the slow domains as these were overwhelming dominated by matrix compartments (93.5%) 
and patches were only 6.5%. At a glance these two kinetically different DA domains are made up 
of two very distinct compartments. These are astonishing results that have not been reported 
before in the literature. Comparisons between the sub- region locations, MS and LS, versus patch 
and matrix compartments (Figure 6.11B) were also very interesting and informative. The patches 
present in the MS were 16.7% whereas the matrix was the predominated structure, 83.3% of this 
region. The LS region appeared to have each distribution of matrix and patch compartments 
(50% for both). 
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Figure 6.10. A comparison of patch and matrix compartments of the MS and LS and corresponding electrode 
locations for collection of evoked DA recordings of seven striatal tissue sections. Top panel represents the MS track 
electrode and the bottom panel represents the LS electrode track. Areas within the striatum that are not highlighted 
in green are the matrix compartments. The LS track has more fast domains and the medial track has more slow 
domains. 
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Figure 6.11. Donut plots of DA kinetic domains (fast and slow) and their anatomical architecture versus their sub-
regions, LS and MS. Panel (A) represents the type of evoked DA response and their classification versus their 
location in patches (red) or matrix (blue).  Panel (B) represents their sub-regions, LS and MS verse their location in 
patches (red) or matrix (blue). 
6.3.9 Distance Dependence between Patch Compartments and Fast Domains 
Our studies have examined the relationship between the patches-matrix and fast and slow evoked 
DA responses. We have only given consideration between these relationships if the electrode 
came into physical contact with patches. We now examine this relationship by looking at the 
distribution of the patches to fluorescence intensities and distance. Images were converted to 
surface intensity plots as demonstrated in Figure S6.2. The use of surface intensity plots shows 
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the distribution and pattern of fluorescence intensities in a 3-D topographical display, in this 
particular case blue represents the lowest intensity and pink the highest intensity. 
We examined if physical contact between the patch and the electrode was a requirement 
which affected the corresponding DA kinetic profile or was there a distant dependence associate 
with the patches which distinguish the domains as fast or slow. In these measurements the 
subcallosal streak was excluded. Figure 6.12 demonstrates two distinctive kinetic profiles of DA 
in the LS. In this LS electrode track; all but one evoked DA response was classified as fast 
domains (red). The highest intensities, pink colors, are considered patches. Circles with 
distinctive diameters were drawn around the highest intensities to measure distances between the 
patches and the electrode track. Similar analysis was performed on MS (data not shown) 
however, in most of these surface intensity plots no patches were present, indicated by an 
absence of pink-red colors. These compartments are matrix (MOR poor) and are governed by 
slow domains, whereas in the patches (MOR rich) compartments the majority of DA domains are 
fast. Interestingly, fast domains are within 300 µm of the evoked DA recording site. In most 
situations, the closer the patches are to the electrode the high probability that the DA kinetics 
will be fast domains, this is evident in the LS panel. More studies need to be performed in the LS 
to provide the relationship between the distance of the electrode and the patches. 
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Figure 6.12. Illustrates surface intensity plots of LS-fast kinetic domains. The electrode track is in the center of the 
image. Most of the DA domains are fast (red) except for one. The length of the electrode is 200 µm; gray horizontal 
lines divide the individual evoked DA responses as the electrode traveled dorsal to ventral through brain tissue. 
Circles with distinctive diameters have been drawn around the highest intensities to measure distance. Intensity axis 
is at the top of each panel ranging from 0 (lowest) - 255 (highest). 
6.4 CONCLUSIONS 
In this study we have amassed a body of evidence showing that the DA terminal fields in the 
striatum of the rat brain are organized as fast and slow kinetic domains which corresponds to the 
biomarkers of striatal architecture, patch-matrix compartments. Comprehensive high resolution 
mapping in the MS and LS was performed using FSCV and correlated to patch-matrix 
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compartments. The majority of fast kinetic domains were located in the LS and the slow kinetic 
domains were more abundant in the MS. Interestingly, our findings conclude that the patch 
compartments correspond to fast domains and the slow domains to the matrix compartments. The 
closer the patches are in proximity to the recording site (~300µm) the more likely the kinetics is 
governed by fast domains; however a larger study will need to be performed. Because the 
domains are a feature of DA terminal fields in the striatum, and the mosaic organization of the 
patch-matrix reflects multiple levels of functional compartments we question “is there 
physiological significance?” Future studies include correlating other DA protein markers such as 
D2 autoreceptors, DAT and TH with DA kinetic domains.  Another important consideration is 
characterizing how these striatal domains and compartments coordinated to cognitive and motor 
behavior. 
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6.5 SUPPLEMENTAL INFORMATION 
Figure S 6.1. A representative image of striatal patches identified by MOR immunohistochemistry staining. A) 
Using threshold settings patches were identified, numbered and outlined. B) Same image of (A) but only the 
outlined and numbered patches are shown. C) is the corresponding DIC image of (A) but image (B) has been 
superimposed on to it. Image (C) is used to confirm the patches are not non-specific binding of the µ-opiate receptor 
to myelinated axon bundles. Red circle in Image (A) corresponds to the location of the lesion. Scale bar is 500µm. 
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Figure S 6.2. Images of LS of the rat stained for MOR rich and poor compartments. A) Labeling of MOR rich 
compartments (patches). B) Corresponding patches are outlined in green. C) Images 10A is converted into a surface 
intensity plot. The intensity axis is located to the right of image (0 lowest intesity-255 highest intensity). The red 
circle indicates the location of the electrolytic lesion. The electrode track is shown in red and blue in each image. 
Scale bar is 500µm. 
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7.0  CONCLUSION 
This dissertation details the potential of the in vivo techniques of microdialysis and voltammetry 
and their impact on understanding dopamine (DA) activity in the brain. 
Microdialysis probe implantation disrupts DA activity in surrounding tissue; however DA 
terminals survive implantation, but cannot function on a normal level due to the probe induced 
penetration injury. Retrodialysis of the anti-inflammatory drug, dexamethasone (DEX), and the 
reactive oxygen species (ROS) scavenger, XJB-5-131, improved the health of the tissue around 
the probe which directly correlated to protection of striatal DA activity as assess by voltammetry 
near probes.32 Initial investigations focused on four hour mitigation of the penetration injury 
directing us to the idea that acute mitigation of tissue damage could potentially chronically 
preserve tissue health. 
Microdialysis in brain tissue is known to cause progressive neurochemical and 
histological disruptions in surrounding tissue.18, 26, 42-43 As many microdialysis experiments are 
performed during a 4-24 hour time period, continued protection of DA activity is necessary. We 
proved that retrodialysis of DEX preserved DA activity for 24 hours through its anti-
inflammatory actions on the surrounding tissue.33 The actions of DEX are restricted to the tissue 
immediately adjacent to the probe, suggesting the DEX enhanced microdialysis is suitable for 
neurochemical monitoring, without having a global effect on the brain. The DA terminal marker 
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tyrosine hydroxylase, rebounded from 4 to 24 hours indicating the continued survival of DA 
terminals near the probe and justifying of our efforts to protect of these terminals. 
A variety of other pharmaceutical agents proved to be effective at preserving DA activity 
in tissue surrounding microdialysis probes. Pharmacologically enhanced microdialysis is not 
limited to DEX, but can be achieved using non-steroidal anti-inflammatories, ibuprofen and 
PPads and novel ROS scavenger JRS527. General protection of the tissue health preserves DA 
activity. 
Microdialysis is widely used to recovery not only DA, but many other small signaling 
molecules in the brain (neurotransmitters, amino acids, neuropeptides, ions).  This method is an 
approved in vivo technique for monitoring traumatic brain injured patients therefore it is 
imperative that microdialysis performs at its full potential. We have performed a preliminary 
study investigating the effect of probe implantation on the ability to measure spreading 
depolarizations (marked by increases in extracellular potassium) in surrounding tissue. Probe 
implantation had no effect on measuring spreading depolarizations 1 mm away as assessed by 
potassium ion selective microelectrodes. Further work must be done to determine the effects, if 
any, on potassium measurements in tissue directly adjacent to the probe. 
Microdialysis is often used to understand brain function and investigate neurological 
disorders. Understanding the penetration injury associated with probe implantation and providing 
protective strategies promotes long-term sampling by microdialysis and plays a lasting role in 
understanding the neurochemistry of the brain. The future of chronic microdialysis is unlimited. 
Microdialysis could be used to determine treatment for traumatic brain injury, to explore the 
development of a progressive neurological disease in a single animal, such as Parkinson’s 
 122 
disease and to continuously monitor different neurochemicals at all stages of substance abuse 
(addition, withdraw, relapse) in a single animal. 
Finally, voltammetry coupled to carbon fiber microelectrodes was used to investigate DA 
neurotransmission in a more discrete manner. The small size of the electrodes provides excellent 
spatial and temporal resolution to map different kinetic DA domains in particular regions of the 
rat striatum. Sub-regions of the striatum were found to be distinct with respect to DA kinetic 
diversity.154 Through voltammetry and histochemistry, DA terminal fields were determined to be 
anatomically organized depending on the initial rate of DA release in either patch or matrix 
compartments present in the striatum. As different sub-regions of the striatum are functionally 
distinct, the current findings show the importance of DA kinetics on DA function in the brain. 
These sub-regions are known to have distinct physiological functions so it makes sense that 
different types of DA signaling exist in different regions. Further insight into understanding the 
relationship between different DA kinetics and functionality can provide insight into drug 
addiction and neurological diseases such as Parkinson’s disease. 
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